| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Cardiovascular System | ||
Phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Cardiovascular System | ||
Phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Cardiovascular System |
Recent Updates
Recently added Catalysts
Lexicon Pharmaceuticals, Inc.$2.24
+0.02 (+1.05%)
B 68Pipeline Score Undervalued Pharma · Commercial
Market Cap
959.46 M
EPS
-0.07
P/E Ratio
-
Value Trade
4.93 M
SEC Financials
Q1 2026Dilution Risk
Revenue
21.10 M
R&D Expenses
12.76 M
Operating CF
-14.73 M
Total Assets
268.82 M
Total Liabilities
65.96 M
Equity
202.86 M
D/E Ratio
12,345
-5.47 %
Week
16.76 %
1 Month
44 %
3 Month
63.64 %
6 Month
-50.46 %
5 Year
-98.6 %
All Time
Cash Data
Cash Position
170.66 M
Monthly Burn
4.91 M
Runway
32.6 mo
Burn Trend
StableSEC Filing
May 7, 2026
Overview
Volume
2.74 M
52 Week Range
0.62 - 2.53
% held by Insiders
51.75 %
% held by Institutions
29.17 %
Enterprise Value
846.52 M
Total Shares
444.20 M
Short %
14.36 %
Float Shares
225.65 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Lexicon Pharmaceuticals, Inc.
216Total events
4Upcoming
59Tier-1 (high impact)
2009 – 2027Coverage
Upcoming catalysts 2
TBD
T2Trial Completion
Subscribe to view catalyst details
TBD
T1Topline Readout
Subscribe to view catalyst details
Event history 2
TBD
◆Oral PresentationPresentation
Subscribe to view catalyst details
TBD
◆Enrollment CompletesotagliflozinApprovedTrial
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-03-28 | Sotagliflozin | phase 3 data readout | Phase 3 | — | – | – | – |
2026-03-28 | Sotagliflozin | phase 3 data readout | Phase 3 | — | – | – | – |
2026-03-28 | Sotagliflozin | phase 3 data readout | Phase 3 | — | – | – | – |
Drug Pipeline Intelligence
B68
Pipeline Score $8.1B
Pipeline ValueUndervalued
Valuation Signal14
Drugs Scored8.5x
rNPV / MCap Top 93%
Micro Cap (rank 65 of 912)
Percentile RankLexicon Pharmaceuticals, Inc. holds a solid B-grade pipeline (68/100), with $20.3B risk-adjusted pipeline value, led by Sotagliflozin in Type 1 Diabetes Mellitus (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sotagliflozin Low Dose Small molecule | Type 1 Diabetes (T1D) | Phase 3 | NCT07211802 | 58% | $13.6B | NOT YET_RECRUITING | 52 | - | - | Dec 31, 2030 | - | LOW May 24, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
pilavapadin | diabetic peripheral neuropathic pain (DPNP) | Phase 2b | 2026-04-17 | nominally significant reduction in Average Pain at Week 8 versus placebo; completion rates comparable to placebo; few discontinuations due to treatment emergent adverse events (TEAEs) Read More | Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting Read More | |
pilavapadin | diabetic peripheral neuropathic pain (DPNP) | Phase 2b | 2026-04-17 | nominally significant reduction in Average Pain at Week 8 versus placebo; completion rates comparable to placebo; few discontinuations due to treatment emergent adverse events (TEAEs) Read More | Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting Read More | |
pilavapadin | diabetic peripheral neuropathic pain (DPNP) | Phase 2b | 2026-04-17 | nominally significant reduction in Average Pain at Week 8 versus placebo; completion rates comparable to placebo; few discontinuations due to treatment emergent adverse events (TEAEs) Read More | Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in LXRX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
LXRX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
LXRXLexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions
Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions
Read more →LXRXLexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
Lexicon Pharmaceuticals will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026. The event will take place in New York City at 2:00 p.m. ET. Attendees can access the live event and replay via the company's website. Lexicon focuses on developing innovative medicines for various medical conditions.
Read more →LXRXLexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference
Lexicon Pharmaceuticals will participate in a fireside chat at the 4th Annual H.C. Wainwright BioConnect Investor Conference on May 19, 2026. The event will be held at the Nasdaq World Headquarters in New York City. Interested parties can access the live event and its replay through the company's website.
Read more →LXRXLexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates
Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates
Read more →LXRXLexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital
Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital
Read more →LXRXLexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
Lexicon Pharmaceuticals will announce its first quarter 2026 financial results on May 7, 2026, before the market opens. A conference call and live webcast will follow at 8:30 a.m. ET to discuss the results and provide a business update. The company is focused on developing transformative medicines across several therapeutic areas.
Read more →LXRXLexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting
Lexicon Pharmaceuticals announced that it will present data from its PROGRESS Phase 2b study of pilavapadin at the AAN Annual Meeting. The study supports the selection of 10 mg as the optimal dose for Phase 3 development in diabetic peripheral neuropathic pain (DPNP). Additionally, data on spasticity endpoints will be presented, highlighting the broader potential of the AAK1 pathway in neurologic diseases.
Read more →LXRXLexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo
Lexicon Pharmaceuticals announced three presentations of sotagliflozin clinical data at the ACC Annual Meeting. The data from the Phase 3 SCORED study indicated that sotagliflozin effectively reduced heart failure and major adverse cardiovascular events, regardless of BMI. Additional analyses from the SOTA-P-CARDIA trial showed improvements in quality of life for non-diabetic patients with heart failure.
Read more →LXRX▲ +5.1%on this newsshared move
Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851
Lexicon Pharmaceuticals and Novo Nordisk have announced the initiation of a Phase 1 study for LX9851, an oral candidate aimed at treating obesity and metabolic disorders. Lexicon has secured a second milestone payment of $10 million and stands to earn up to $1 billion in total payments from the collaboration. The study will assess the safety and efficacy of LX9851 in 96 participants, with completion expected by Q1 2027.
Read more →LXRXLexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes
Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes
Read more →LXRXLexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates
Lexicon Pharmaceuticals reported its financial results for Q4 2025, highlighting significant progress in its clinical pipeline, including the advancement of pilavapadin into Phase 3 and ongoing enrollment in the SONATA study for HCM. The company secured over $100 million in funding, bolstering its financial position. Despite a net loss, Lexicon remains optimistic about its future prospects and upcoming milestones.
Read more →LXRXLexicon Pharmaceuticals to Participate in Three Upcoming March 2026 Investor Conferences
Lexicon Pharmaceuticals announced its participation in three investor conferences in March 2026. The company will engage in a fireside chat at the Leerink Partners Global Healthcare Conference and hold 1x1 meetings at the Jefferies Biotech on the Beach Summit and Barclays Global Healthcare Conference. This involvement highlights Lexicon's commitment to investor relations and showcases its ongoing development efforts.
Read more →LXRXLexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026
Lexicon Pharmaceuticals announced it will release its fourth quarter 2025 financial results on March 5, 2026. The company will host a conference call at 8:30 a.m. ET to discuss these results and provide a business update. Participants can access the call via webcast and will have the opportunity to ask questions.
Read more →LXRXLexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
Lexicon Pharmaceuticals has announced the successful closing of a public offering, raising approximately $94.6 million through the sale of 32 million shares of common stock and a concurrent private placement. The proceeds will be utilized for research and development of drug candidates and general corporate purposes. The company granted underwriters an option to purchase additional shares, enhancing potential funding.
Read more →LXRX▼ -19.4%on this news
Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
Lexicon Pharmaceuticals has announced the pricing of a public offering of 32 million shares at $1.30 each, expected to raise $41.6 million. Concurrently, a private placement is set to generate approximately $41.1 million. The proceeds will be used for research and development and general corporate purposes. The offerings are scheduled to close on February 2, 2026.
Read more →LXRX▼ -19.4%on this newsshared move
Lexicon Announces Proposed Public Offering of Common Stock - January 29, 2026
Lexicon Pharmaceuticals has announced a proposed public offering of common stock to fund its drug development and general corporate purposes. The offering includes an option for underwriters to purchase additional shares. Concurrently, Lexicon plans a private placement with its largest stockholder, Invus, L.P. The company has a robust pipeline in various therapeutic areas.
Read more →LXRXLEXICON ANNOUNCES PRICING OF APPROXIMATELY $94.6 MILLION PUBLIC OFFERING AND CONCURRENT PRIVATE PLACEMENT The Woodlands, Texas
Lexicon Pharmaceuticals has priced its public offering at approximately $94.6 million, selling 32 million shares at $1.30 each. The gross proceeds are intended to fund ongoing research and development of its drug candidates, as well as to cover general corporate expenses. Complementing this public offering, Lexicon will conduct a concurrent private placement with significant participation from its largest stockholder, Invus, L.P. Both offerings are slated to close around February 2, 2026.
Read more →LXRXLexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary
Lexicon Pharmaceuticals will ring the Nasdaq Closing Bell on January 27, 2026, to celebrate its 30th anniversary. The event highlights the company's evolution and commitment to developing therapies for cardiometabolic diseases and chronic pain. CEO Mike Exton emphasized Lexicon's dedication to medical research and innovation over the past three decades.
Read more →LXRX▲ +12.8%on this newsshared move
Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain
Lexicon Pharmaceuticals announced a successful End-of-Phase 2 meeting with the FDA regarding pilavapadin for diabetic peripheral neuropathic pain. The FDA did not raise any objections to moving forward into Phase 3 development, which will involve two placebo-controlled studies. The primary endpoint will be the change in average daily pain score over 12 weeks.
Read more →LXRXViatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure
Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure
Read more →LXRXLexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference
Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference
Read more →LXRXLexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain”
Lexicon Pharmaceuticals has published a white paper titled 'Relief is Possible,' summarizing discussions from a Roundtable held in October 2025. The paper emphasizes the urgent need for policymakers to enhance access to effective non-opioid treatments for chronic pain, which affects millions of Americans. The Relief of Chronic Pain Act aims to ensure Medicare coverage for these therapies, highlighting the importance of bipartisan efforts to address this widespread issue.
Read more →LXRXLexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Lexicon Pharmaceuticals will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026. The presentation will be accessible live and via replay on the company's website. Lexicon is known for its pioneering medicines and has a strong pipeline in various therapeutic areas.
Read more →LXRXLexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851
Lexicon Pharmaceuticals announced the publication of preclinical data in the Journal of the Endocrine Society, validating Acyl-CoA Synthetase 5 (ACSL5) as a target for obesity treatment. The data indicates that mice lacking ACSL5 exhibited improved metabolic characteristics. The investigational drug LX9851, a small molecule inhibitor of ACSL5, is positioned to advance in clinical development following a licensing agreement with Novo Nordisk.
Read more →LXRXClinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum
Lexicon Pharmaceuticals will present clinical data on sotagliflozin's effects on adipose tissue distribution in non-diabetic patients at the 2025 Global Cardio Vascular Clinical Trialists Forum. The data comes from a randomized trial involving patients with heart failure with preserved ejection fraction. This presentation aims to highlight sotagliflozin's unique benefits compared to traditional SGLT2 inhibitors.
Read more →LXRXLexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences
Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences
Read more →LXRX▲ +9.9%on this news
Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference
Lexicon Pharmaceuticals will participate in a fireside chat at the Jefferies 2025 London Healthcare Conference on November 18. The event will provide an opportunity for company management to discuss their innovative medicines and pipeline. Lexicon focuses on genomics and has advanced multiple medicines to market, targeting various diseases.
Read more →LXRX▲ +13.6%on this news· ran to +25% by day 1shared move
Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025
Lexicon Pharmaceuticals presented new clinical data on sotagliflozin at the AHA Annual Scientific Sessions 2025. The study focused on heart failure patients with preserved ejection fraction (HFpEF) without diabetes, showing significant improvements in cardiac function and quality of life. This research is pivotal as it highlights the potential of sotagliflozin in a previously underserved patient population.
Read more →LXRXLexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates
Lexicon Pharmaceuticals reported strong financial results for Q3 2025, with revenues increasing significantly to $14.2 million. The company highlighted key R&D updates, including the completion of IND-enabling studies for LX9851 and progress in the SONATA-HCM Phase 3 study. Despite a net loss of $12.8 million, Lexicon remains optimistic about its pipeline and strategic initiatives for 2026.
Read more →LXRXData Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association’s Sessions 2025 in New Orleans
Lexicon Pharmaceuticals announced that data from three studies of sotagliflozin will be presented at the upcoming AHA and HCMS Scientific Sessions 2025. The presentations aim to showcase the unique benefits of sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, across various patient populations. Lexicon's ongoing research continues to explore its potential in treating conditions like heart failure and hypertrophic cardiomyopathy.
Read more →LXRXLexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
Read more →LXRXLexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit
Lexicon Pharmaceuticals presented new data on pilavapadin for diabetic peripheral neuropathic pain at the 19th Annual Pain Therapeutics Summit. The company confirmed the 10 mg dose's readiness for Phase 3 development following positive analyses from their Phase 2 studies. The FDA has accepted their end-of-Phase 2 meeting request, and discussions with potential partners are ongoing.
Read more →LXRX▼ -5.9%on this news
Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain
Lexicon Pharmaceuticals hosted a roundtable to discuss improving public policy for chronic pain sufferers. Experts emphasized the need for legislative changes to include chronic pain in the Alternatives to PAIN Act. The meeting highlighted the importance of innovation in pain treatment and the potential for non-opioid therapies. Lexicon plans to release a White Paper detailing the discussion outcomes.
Read more →LXRXLexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes
Lexicon Pharmaceuticals has updated its submission of additional clinical data to the FDA regarding Zynquista, an oral SGLT1/SGLT2 inhibitor for type 1 diabetes. This follows a complete response letter from December 2024 due to concerns about diabetic ketoacidosis. The FDA is expected to provide feedback from a Type D meeting in the fourth quarter of 2025.
Read more →LXRXPilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings
Lexicon Pharmaceuticals presented positive Phase 2b PROGRESS study results for pilavapadin, an investigational treatment for diabetic peripheral neuropathic pain (DPNP). The study indicated that the 10 mg dose of pilavapadin significantly reduced average daily pain scores. The company aims to advance to Phase 3 trials, highlighting the drug's potential as a novel non-opioid therapy for DPNP.
Read more →LXRXLexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings
Lexicon Pharmaceuticals announced that it will present clinical data on pilavapadin, an investigational drug for diabetic peripheral neuropathic pain (DPNP), at three upcoming medical meetings. The presentations will highlight the breadth of data from the Phase 2 program. Pilavapadin is a selective AAK1-inhibitor that aims to improve pain management without affecting opiate pathways.
Read more →LXRXLexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes
Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes
Read more →LXRXLexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025
Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025
Read more →LXRXLexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025
Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025
Read more →LXRXSotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 Congress
Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 Congress
Read more →LXRXLexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences
Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences
Read more →LXRX▲ +9.5%on this news
Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates
Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates
Read more →LXRXLexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
Lexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
Read more →LXRXLexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025
Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025
Read more →LXRX▼ -8.9%on this newsshared move
Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025)
Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025)
Read more →LXRXData Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA)
Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA)
Read more →LXRXLexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)
Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)
Read more →LXRX▼ -5.7%on this news
Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
Read more →LXRXSONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology
SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology
Read more →LXRX▼ -6.5%on this news· ran to -21% by day 1
Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates
Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates
Read more →LXRX▼ -8.9%on this news
Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference
Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference
Read more →LXRX▼ -8.9%on this news
Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025
Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025
Read more →LXRX▲ +8.4%on this news
Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
Read more →LXRX▲ +64.1%on this newsshared move
Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851
Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851
Read more →LXRX▲ +6.6%on this news
Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025
Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025
Read more →LXRX▲ +9.4%on this newsshared move
Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
Read more →LXRX▲ +11%on this news· ran to +34% by day 3shared move
Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
Read more →LXRX▼ -58.2%on this newsshared move
Lexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain
Lexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain
Read more →LXRX▼ -58.2%on this newsshared move
Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain
Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain
Read more →LXRXPublished Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE)
Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE)
Read more →LXRX▲ +14.2%on this news· ran to +43% by day 3
Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain
Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain
Read more →LXRX▲ +5.2%on this news· ran to +26% by day 3
Lexicon Appoints Scott Coiante as Chief Financial Officer
Lexicon Appoints Scott Coiante as Chief Financial Officer
Read more →LXRXLexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)
Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)
Read more →LXRXLexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
Read more →LXRX▼ -5.8%on this newsshared move
Lexicon Pharmaceuticals to Participate in December Investor Conferences
Lexicon Pharmaceuticals to Participate in December Investor Conferences
Read more →LXRX▲ +11.9%on this newsshared move
Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA
Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA
Read more →LXRX▼ -8.3%on this newsshared move
Lexicon Appoints Ivan H. Cheung to Board of Directors
Lexicon Appoints Ivan H. Cheung to Board of Directors
Read more →LXRXPost-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association's (AHA) Sessions 2024 in Chicago
Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association's (AHA) Sessions 2024 in Chicago
Read more →LXRX▼ -6.3%on this news· ran to -23% by day 3shared move
Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
Read more →LXRXLexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference
Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference
Read more →LXRXPublished Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People With Type 1 Diabetes and Chronic Kidney Disease
Published Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People With Type 1 Diabetes and Chronic Kidney Disease
Read more →LXRXLexicon Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 12, 2024
Lexicon Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 12, 2024
Read more →LXRXLexicon to Present Preclinical IN VIVO Efficacy Data Demonstrating Ability of New Investigational Compound to Enhance and Maintain Semaglutide-Promoted Weight Loss
Lexicon to Present Preclinical IN VIVO Efficacy Data Demonstrating Ability of New Investigational Compound to Enhance and Maintain Semaglutide-Promoted Weight Loss
Read more →LXRX▼ -37.4%on this newsshared move
Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease
Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease
Read more →LXRXNew Analysis of Phase 3 Data Demonstrating Renal Protective Benefits of Sotagliflozin to be Presented at ASN Kidney Week 2024
New Analysis of Phase 3 Data Demonstrating Renal Protective Benefits of Sotagliflozin to be Presented at ASN Kidney Week 2024
Read more →LXRXLexicon Announces Completion of Screening in Phase 2B Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
Lexicon Announces Completion of Screening in Phase 2B Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
Read more →LXRX▲ +6.7%on this news
Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe
Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe
Read more →LXRX▲ +6.7%on this news
Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe
Lexicon Pharmaceuticals has entered into an exclusive licensing agreement with Viatris for the commercialization of sotagliflozin in markets outside the U.S. and Europe. The agreement allows Viatris to manage all regulatory and commercialization activities in exchange for an upfront payment of $25 million. Lexicon retains rights to sotagliflozin in the U.S. and Europe, continuing their critical strategic partnerships to enhance global medicine access. This collaboration aims to leverage Viatris's capabilities in addressing cardiovascular diseases as they expand their innovative portfolio.
Read more →LXRXLexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress
Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress
Read more →LXRXLexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer
Lexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer
Read more →LXRXNew Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes
New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes
Read more →LXRX▼ -6.9%on this news
Lexicon Pharmaceuticals to Participate in Upcoming September Investor Conferences
Lexicon Pharmaceuticals to Participate in Upcoming September Investor Conferences
Read more →LXRX▼ -6.9%on this news
New Secondary Analysis of Phase 3 Data Demonstrates that INPEFA® (Sotagliflozin) Benefited Heart Failure Patients Regardless of Diabetes Duration
New Secondary Analysis of Phase 3 Data Demonstrates that INPEFA® (Sotagliflozin) Benefited Heart Failure Patients Regardless of Diabetes Duration
Read more →LXRX▲ +13.7%on this news
Lexicon Pharmaceuticals Announces FDA Advisory Committee Meeting for Zynquista
Lexicon Pharmaceuticals Announces FDA Advisory Committee Meeting for Zynquista
Read more →LXRX▲ +8.8%on this news
Lexicon Pharmaceuticals Announces Strategic Repositioning to Drive Value and Growth of Commercial Portfolio
Lexicon Pharmaceuticals Announces Strategic Repositioning to Drive Value and Growth of Commercial Portfolio
Read more →LXRXEfficacy and Safety Data of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Disease Among Three Lexicon-Sponsored Presentations at the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists
Efficacy and Safety Data of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Disease Among Three Lexicon-Sponsored Presentations at the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists
Read more →LXRX▼ -10.2%on this news· ran to -27% by day 3
Lexicon Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
Lexicon Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
Read more →LXRX▲ +7.4%on this news
Lexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024
Lexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024
Read more →LXRX▲ +5.2%on this news
Lexicon Pharmaceuticals Receives December 20, 2024 PDUFA Goal Date for Sotagliflozin Type 1 Diabetes NDA Resubmission
Lexicon Pharmaceuticals Receives December 20, 2024 PDUFA Goal Date for Sotagliflozin Type 1 Diabetes NDA Resubmission
Read more →LXRX▲ +7.1%on this newsshared move
New Published Data Highlights Potential Cost-Savings of INPEFA® (sotagliflozin) for Heart Failure
New Published Data Highlights Potential Cost-Savings of INPEFA® (sotagliflozin) for Heart Failure
Read more →LXRXLexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director
Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director
Read more →LXRX▲ +5.7%on this news
Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes
Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes
Read more →LXRXData From Lexicon's RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association
Data From Lexicon's RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association
Read more →LXRXAnalysis of INPEFA® (Sotagliflozin) Cost-Effectiveness Published in JACC: Heart Failure, the Peer-Reviewed Journal of the American College of Cardiology
Analysis of INPEFA® (Sotagliflozin) Cost-Effectiveness Published in JACC: Heart Failure, the Peer-Reviewed Journal of the American College of Cardiology
Read more →LXRXFindings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes Association
Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes Association
Read more →LXRXLexicon Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2024
Lexicon Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2024
Read more →LXRXNew Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA® (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction
New Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA® (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction
Read more →LXRX▲ +6.8%on this newsshared move
Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024
Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024
Read more →LXRXLexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
Read more →LXRXLonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon Pharmaceuticals
Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon Pharmaceuticals
Read more →LXRXLexicon Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 2, 2024
Lexicon Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 2, 2024
Read more →LXRXLexicon Pharmaceuticals to Host 2024 Investor Day
Lexicon Pharmaceuticals to Host 2024 Investor Day
Read more →LXRX▼ -7.7%on this news
Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Read more →LXRX▼ -6.2%on this news
Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo
Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo
Read more →LXRX▼ -10.3%on this news
New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease
New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease
Read more →LXRX▲ +29.5%on this newsshared move
Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update
Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update
Read more →LXRX▲ +29.5%on this newsshared move
Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities
Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities
Read more →LXRX▲ +29.5%on this newsshared move
Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA
Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA
Read more →LXRX▲ +29.5%on this newsshared move
LEXICON PHARMACEUTICALS REPORTS FOURTH QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Commercial launch of INPEFA (sotagliflozin) continues to progress. with increasing dem
Lexicon Pharmaceuticals reported its fourth quarter 2023 financial results, highlighting the successful commercial launch of INPEFA (sotagliflozin) and ongoing demand within the cardiology sector. The company is advancing its pipeline with patient enrollment in a Phase 2b study of LX9211 and preparing for a Phase 3 study of sotagliflozin in hypertrophic cardiomyopathy. Financially, Lexicon experienced increased net losses and R&D expenses but has raised capital to support future initiatives and growth. The company plans to hold an Investor Day on April 22, 2024, to discuss business and regulatory updates.
Read more →LXRXLexicon Pharmaceuticals Provides Business and Pipeline Update at 42nd Annual J.P. Morgan Healthcare Conference
Lexicon Pharmaceuticals Provides Business and Pipeline Update at 42nd Annual J.P. Morgan Healthcare Conference
Read more →LXRXLexicon Pharmaceuticals To Participate In The 42nd Annual JPMorgan Healthcare Conference
Lexicon Pharmaceuticals To Participate In The 42nd Annual JPMorgan Healthcare Conference
Read more →LXRXLexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
Read more →LXRXLexicon Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference and the 6th Annual Evercore ISI HealthCONx Conference
Lexicon Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference and the 6th Annual Evercore ISI HealthCONx Conference
Read more →LXRX▲ +5.9%on this news
INPEFA® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data
INPEFA® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data
Read more →LXRXLexicon Pharmaceuticals to Participate in the Jefferies London Healthcare Conference
Lexicon Pharmaceuticals to Participate in the Jefferies London Healthcare Conference
Read more →LXRX▼ -8.8%on this newsshared move
Lexicon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
Lexicon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
Read more →LXRX▲ +5.7%on this news· ran to -19% by day 3shared move
Lexicon Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call and Webcast on November 8, 2023
Lexicon Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call and Webcast on November 8, 2023
Read more →LXRXData on Early Clinical Benefit for INPEFA® (Sotagliflozin) Will Be Among Five Lexicon-Sponsored Presentations at the American Heart Association Scientific Sessions 2023
Data on Early Clinical Benefit for INPEFA® (Sotagliflozin) Will Be Among Five Lexicon-Sponsored Presentations at the American Heart Association Scientific Sessions 2023
Read more →LXRX▲ +8.1%on this newsshared move
INPEFA® (Sotagliflozin) Receives Coverage From Express Scripts on Its Basic and High Performance Formularies for Commercially Insured Patients
INPEFA® (Sotagliflozin) Receives Coverage From Express Scripts on Its Basic and High Performance Formularies for Commercially Insured Patients
Read more →LXRXLexicon Strengthens Management Team With Two New Executives
Lexicon Strengthens Management Team With Two New Executives
Read more →LXRX▲ +8.1%on this news· ran to +26% by day 3shared move
New Data Relating to Sotagliflozin to be Presented at the American Society of Nephrology (ASN) Kidney Week 2023 Annual Meeting
New Data Relating to Sotagliflozin to be Presented at the American Society of Nephrology (ASN) Kidney Week 2023 Annual Meeting
Read more →LXRX▼ -8.1%on this news
Data From Two Studies Demonstrating Positive Financial Impact of INPEFA® (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting
Data From Two Studies Demonstrating Positive Financial Impact of INPEFA® (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting
Read more →LXRXData Demonstrating Financial Impact of INPEFA® (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting
Data Demonstrating Financial Impact of INPEFA® (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting
Read more →LXRX▼ -7.4%on this newsshared move
INPEFA® (Sotagliflozin) Receives Preferred Formulary Status With Express Scripts For Medicare Patients
INPEFA® (Sotagliflozin) Receives Preferred Formulary Status With Express Scripts For Medicare Patients
Read more →LXRX▼ -7.4%on this newsshared move
Tom Garner Joins Lexicon as Senior Vice President and Chief Commercial Officer
Tom Garner Joins Lexicon as Senior Vice President and Chief Commercial Officer
Read more →LXRX▼ -9.1%on this news
Lexicon to Present Post Hoc Analysis of Scored Clinical Trial at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2023
Lexicon to Present Post Hoc Analysis of Scored Clinical Trial at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2023
Read more →LXRX▲ +10.4%on this newsshared move
Lexicon to Present Study Results Relating to Sotagliflozin and LX9211 at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD)
Lexicon to Present Study Results Relating to Sotagliflozin and LX9211 at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD)
Read more →LXRXLexicon Announces Series of Presentations Relating to LX9211, Its Investigational Drug for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)
Lexicon Announces Series of Presentations Relating to LX9211, Its Investigational Drug for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)
Read more →LXRXLexicon Pharmaceuticals to Participate in the H.C. Wainwright & Co. 25th Annual Global Investment Conference
Lexicon Pharmaceuticals to Participate in the H.C. Wainwright & Co. 25th Annual Global Investment Conference
Read more →LXRXLexicon to Present Analyses of INPEFA™ (sotagliflozin) Clinical Study Results and Changing Patterns of Heart Failure Diagnoses at the European Society of Cardiology (ESC) Congress 2023
Lexicon to Present Analyses of INPEFA™ (sotagliflozin) Clinical Study Results and Changing Patterns of Heart Failure Diagnoses at the European Society of Cardiology (ESC) Congress 2023
Read more →LXRX▲ +7.1%on this news
Published Analysis of Sotagliflozin (INPEFA(TM)) Clinical Data Demonstrates Significant Reductions in the Risk of Hospital Readmissions for Heart Failure
Published Analysis of Sotagliflozin (INPEFA(TM)) Clinical Data Demonstrates Significant Reductions in the Risk of Hospital Readmissions for Heart Failure
Read more →LXRXLexicon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
Lexicon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
Read more →LXRXLexicon Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call and Webcast on August 3, 2023
Lexicon Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call and Webcast on August 3, 2023
Read more →LXRXLexicon Elects Diane E. Sullivan to Board of Directors
Lexicon Elects Diane E. Sullivan to Board of Directors
Read more →LXRXLexicon Announces Planned Advancement of LX9211 Into Late-Stage Development
Lexicon Announces Planned Advancement of LX9211 Into Late-Stage Development
Read more →LXRXLexicon to Present Study Results Relating to LX9211 and INPEFA™ (Sotagliflozin) at the American Diabetes Association's 83rd Scientific Sessions
Lexicon to Present Study Results Relating to LX9211 and INPEFA™ (Sotagliflozin) at the American Diabetes Association's 83rd Scientific Sessions
Read more →LXRXUPDATE: Lexicon Announces FDA Approval of INPEFA™ (sotagliflozin) for Treatment of Heart Failure
UPDATE: Lexicon Announces FDA Approval of INPEFA™ (sotagliflozin) for Treatment of Heart Failure
Read more →LXRXLexicon Pharmaceuticals to Participate in the Jefferies 2023 Global Healthcare Conference
Lexicon Pharmaceuticals to Participate in the Jefferies 2023 Global Healthcare Conference
Read more →LXRX▼ -7.5%on this newsshared move
Lexicon Announces Closing of Public Offering and Concurrent Private Placement, Including Full Exercise of Options to Purchase Additional Shares
Lexicon Announces Closing of Public Offering and Concurrent Private Placement, Including Full Exercise of Options to Purchase Additional Shares
Read more →LXRX▼ -17.9%on this newsshared move
LEXICON ANNOUNCES PRICING OF $125 MILLION PUBLIC OFFERING AND CONCURRENT PRIVATE PLACEMENT The Woodlands, Texas
Lexicon Pharmaceuticals has announced the pricing of a $125 million public offering, which includes an underwritten public offering of approximately 23.9 million shares at $2.60 per share. The gross proceeds from the public offering are anticipated to be around $62.2 million, with a concurrent private placement expected to raise an additional approximately $62.8 million. The company plans to use a portion of the proceeds for the commercial launch of its drug INPEFA and for ongoing research and development. The offerings are expected to close on or around June 5, 2023, pending customary closing conditions.
Read more →LXRX▼ -17.9%on this newsshared move
Lexicon Announces Pricing of $125 Million Public Offering and Concurrent Private Placement
Lexicon Announces Pricing of $125 Million Public Offering and Concurrent Private Placement
Read more →LXRX▲ +13.8%on this newsshared move
Lexicon Announces Proposed Public Offering of Common Stock
Lexicon Announces Proposed Public Offering of Common Stock
Read more →LXRX▲ +9.7%on this newsshared move
Lexicon Announces FDA Approval of INPEFA™ (sotagliflozin) for Treatment of Heart Failure
Lexicon Announces FDA Approval of INPEFA™ (sotagliflozin) for Treatment of Heart Failure
Read more →LXRXNew Analysis Finds Sotagliflozin to Be a Cost-Effective Treatment at Commonly Accepted Willingness-to-Pay Threshold in Patients with Worsening Heart Failure
New Analysis Finds Sotagliflozin to Be a Cost-Effective Treatment at Commonly Accepted Willingness-to-Pay Threshold in Patients with Worsening Heart Failure
Read more →LXRXLexicon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
Lexicon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
Read more →LXRXLexicon Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call and Webcast on May 2, 2023
Lexicon Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call and Webcast on May 2, 2023
Read more →LXRXLexicon To Present Results From LX9211 Phase 2 Trial In Postherpetic Neuralgia At The 2023 American Academy Of Neurology Annual Meeting And The British Pain Society 56th Annual Scientific Meeting 2023
Lexicon To Present Results From LX9211 Phase 2 Trial In Postherpetic Neuralgia At The 2023 American Academy Of Neurology Annual Meeting And The British Pain Society 56th Annual Scientific Meeting 2023
Read more →LXRX▲ +11.6%on this news
Lexicon Pharmaceuticals to Participate in The 22nd Annual Needham Virtual Healthcare Conference
Lexicon Pharmaceuticals to Participate in The 22nd Annual Needham Virtual Healthcare Conference
Read more →LXRXNew Analyses of Sotagliflozin Showing Time to Clinical Benefit Presented at The American College of Cardiology's 72nd Annual Scientific Session Together With World Heart Federation's World Congress of Cardiology
New Analyses of Sotagliflozin Showing Time to Clinical Benefit Presented at The American College of Cardiology's 72nd Annual Scientific Session Together With World Heart Federation's World Congress of Cardiology
Read more →LXRXLexicon Reveals "INTO THE DARK" Awareness Campaign About Vulnerable and Dangerous Period of Time Faced by Heart Failure Patients Following Hospitalization
Lexicon Reveals "INTO THE DARK" Awareness Campaign About Vulnerable and Dangerous Period of Time Faced by Heart Failure Patients Following Hospitalization
Read more →LXRXLexicon Pharmaceuticals Reports Fourth Quarter 2022 Financial Results and Provides Business Update
Lexicon Pharmaceuticals Reports Fourth Quarter 2022 Financial Results and Provides Business Update
Read more →LXRXLexicon Pharmaceuticals to Host Fourth Quarter 2022 Financial Results Conference Call and Webcast on March 2, 2023
Lexicon Pharmaceuticals to Host Fourth Quarter 2022 Financial Results Conference Call and Webcast on March 2, 2023
Read more →LXRX▼ -8.6%on this news
New Analyses of Sotagliflozin to Be Presented at the American College of Cardiology's 72nd Annual Scientific Session Together With World Heart Federation's World Congress of Cardiology
New Analyses of Sotagliflozin to Be Presented at the American College of Cardiology's 72nd Annual Scientific Session Together With World Heart Federation's World Congress of Cardiology
Read more →LXRXLexicon Pharmaceuticals to Participate in the 41st Annual JP Morgan Healthcare Conference
Lexicon Pharmaceuticals to Participate in the 41st Annual JP Morgan Healthcare Conference
Read more →LXRXLexicon Announces Topline Results From Phase 2 Proof-of-Concept Study of LX9211 in Postherpetic Neuralgia
Lexicon Announces Topline Results From Phase 2 Proof-of-Concept Study of LX9211 in Postherpetic Neuralgia
Read more →LXRX▼ -5.2%on this news
Lexicon Pharmaceuticals to Participate in the 34th Annual Piper Sandler Healthcare Conference and the 5th Annual Evercore ISI HealthCONx Conference
Lexicon Pharmaceuticals to Participate in the 34th Annual Piper Sandler Healthcare Conference and the 5th Annual Evercore ISI HealthCONx Conference
Read more →LXRXLexicon's LX9211 Shows Significant and Consistent Benefits in the Treatment of Painful Diabetic Neuropathy in Full Results From the Phase 2 RELIEF-DPN-1 Trial Presented at the 16th Annual Pain Therapeutics Summit
Lexicon's LX9211 Shows Significant and Consistent Benefits in the Treatment of Painful Diabetic Neuropathy in Full Results From the Phase 2 RELIEF-DPN-1 Trial Presented at the 16th Annual Pain Therapeutics Summit
Read more →LXRX▲ +5.8%on this newsshared move
Lexicon Pharmaceuticals to Participate in the 13th Annual Jefferies London Healthcare Conference
Lexicon Pharmaceuticals to Participate in the 13th Annual Jefferies London Healthcare Conference
Read more →LXRXLexicon Pharmaceuticals Reports Third Quarter 2022 Financial Results And Provides Business Update
Lexicon Pharmaceuticals Reports Third Quarter 2022 Financial Results And Provides Business Update
Read more →LXRXLexicon Pharmaceuticals Highlights Oral Presentation of Final Results From the RELIEF-DPN-1 Trial of LX9211 at the 16th Annual Pain Therapeutics Summit
Lexicon Pharmaceuticals Highlights Oral Presentation of Final Results From the RELIEF-DPN-1 Trial of LX9211 at the 16th Annual Pain Therapeutics Summit
Read more →LXRXNew Analysis of SOLOIST-WHF Results Demonstrates Sotagliflozin's Significant Effect in Reducing the Risk of Hospital Readmissions for Heart Failure
New Analysis of SOLOIST-WHF Results Demonstrates Sotagliflozin's Significant Effect in Reducing the Risk of Hospital Readmissions for Heart Failure
Read more →LXRXNew Analysis of SCORED Trial Demonstrates Sotagliflozin's Effect on Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease
New Analysis of SCORED Trial Demonstrates Sotagliflozin's Effect on Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease
Read more →LXRXLexicon Pharmaceuticals to Host Third Quarter 2022 Financial Results Conference Call and Webcast on November 9, 2022
Lexicon Pharmaceuticals to Host Third Quarter 2022 Financial Results Conference Call and Webcast on November 9, 2022
Read more →LXRXNew Analyses of Sotagliflozin From the SOLOIST-WHF and SCORED Trials in High Cardiovascular Risk Patients to be Presented at the American Heart Association Scientific Sessions 2022
New Analyses of Sotagliflozin From the SOLOIST-WHF and SCORED Trials in High Cardiovascular Risk Patients to be Presented at the American Heart Association Scientific Sessions 2022
Read more →LXRXLexicon Pharmaceuticals Announces Oral Presentations Relating To Its LX9211 Neuropathic Pain Program At The World Brain Disorders And Neuroscience Summit 2022
Lexicon Pharmaceuticals Announces Oral Presentations Relating To Its LX9211 Neuropathic Pain Program At The World Brain Disorders And Neuroscience Summit 2022
Read more →LXRXNew Analysis of SOLOIST-WHF Trial Underscores Sotagliflozin's Effect on Reducing Recurrent Heart Failure Events
New Analysis of SOLOIST-WHF Trial Underscores Sotagliflozin's Effect on Reducing Recurrent Heart Failure Events
Read more →LXRXLexicon Pharmaceuticals Highlights Scientific and Medical Presentations Relating to Its Successful Phase 2 Proof-Of-Concept Study of LX9211 in Painful Diabetic Neuropathy
Lexicon Pharmaceuticals Highlights Scientific and Medical Presentations Relating to Its Successful Phase 2 Proof-Of-Concept Study of LX9211 in Painful Diabetic Neuropathy
Read more →LXRX▼ -6.5%on this news
Lexicon Pharmaceuticals Highlights Publications Relating to Sotagliflozin's Differentiated Dual SGLT1 and SGLT2 Mechanism of Action and Potential Implications for Cardiovascular Disease
Lexicon Pharmaceuticals Highlights Publications Relating to Sotagliflozin's Differentiated Dual SGLT1 and SGLT2 Mechanism of Action and Potential Implications for Cardiovascular Disease
Read more →LXRX▲ +5.2%on this news
Lexicon Announces Full Exercise and Closing of Options to Purchase Additional Shares in Connection with Previously Announced Public Offering and Concurrent Private Placement
Lexicon Announces Full Exercise and Closing of Options to Purchase Additional Shares in Connection with Previously Announced Public Offering and Concurrent Private Placement
Read more →LXRX▲ +9.7%on this newsshared move
Lexicon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
Lexicon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
Read more →LXRXLexicon Pharmaceuticals to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 2, 2022
Lexicon Pharmaceuticals to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 2, 2022
Read more →LXRX▼ -26.6%on this newsshared move
Lexicon Announces Pricing of $85.0 Million Public Offering and Concurrent Private Placement
Lexicon Announces Pricing of $85.0 Million Public Offering and Concurrent Private Placement
Read more →LXRXLexicon Announces Proposed Public Offering Of Common Stock
Lexicon Announces Proposed Public Offering Of Common Stock
Read more →LXRXLexicon Announces FDA Acceptance of New Drug Application for Sotagliflozin to Treat Heart Failure
Lexicon Announces FDA Acceptance of New Drug Application for Sotagliflozin to Treat Heart Failure
Read more →LXRXLEXICON ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK The Woodlands, Texas
ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK The Woodlands, Texas, July 27, 2022 Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) ( Lexicon ) today announced that it has commenced an underwritten public offering to offer and sell, subject to market and other conditions, share
Read more →LXRXLexicon Announces Positive Top-Line Results From Phase 2 Proof-Of-Concept Study Of LX9211 In Painful Diabetic Neuropathy
Lexicon Announces Positive Top-Line Results From Phase 2 Proof-Of-Concept Study Of LX9211 In Painful Diabetic Neuropathy
Read more →LXRXLexicon Pharmaceuticals to Participate in the Jefferies 2022 Healthcare Conference
Lexicon Pharmaceuticals to Participate in the Jefferies 2022 Healthcare Conference
Read more →LXRXLexicon Resubmits New Drug Application for Sotagliflozin for the Treatment of Heart Failure
Lexicon Resubmits New Drug Application for Sotagliflozin for the Treatment of Heart Failure
Read more →LXRXLexicon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical Update
Lexicon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical Update
Read more →LXRXLexicon Pharmaceuticals to Host First Quarter 2022 Financial Results Conference Call and Webcast on May 5, 2022
Lexicon Pharmaceuticals to Host First Quarter 2022 Financial Results Conference Call and Webcast on May 5, 2022
Read more →LXRX▲ +10.7%on this news
Lexicon Pharmaceuticals to Participate in the 21st Annual Needham Virtual Healthcare Conference
Lexicon Pharmaceuticals to Participate in the 21st Annual Needham Virtual Healthcare Conference
Read more →LXRX▲ +12%on this newsshared move
Lexicon Welcomes New Guidelines for the Management of Heart Failure
Lexicon Welcomes New Guidelines for the Management of Heart Failure
Read more →LXRX▲ +12%on this newsshared move
Sotagliflozin Improved Outcomes in Patients With and Without Prior Cardiovascular Disease in New Analysis Presented at the American College of Cardiology's 71st Annual Scientific Session (ACC.22)
Sotagliflozin Improved Outcomes in Patients With and Without Prior Cardiovascular Disease in New Analysis Presented at the American College of Cardiology's 71st Annual Scientific Session (ACC.22)
Read more →LXRXNew Analysis of Cardiovascular Endpoints in the SCORED Trial to Be Presented at the American College of Cardiology's 71st Annual Scientific Session (ACC.22)
New Analysis of Cardiovascular Endpoints in the SCORED Trial to Be Presented at the American College of Cardiology's 71st Annual Scientific Session (ACC.22)
Read more →LXRXLexicon Enters Into Loan Facility With Oxford Finance for Up to $150 Million to Support Planned Commercialization of Sotagliflozin
Lexicon Enters Into Loan Facility With Oxford Finance for Up to $150 Million to Support Planned Commercialization of Sotagliflozin
Read more →LXRX▼ -27.4%on this news
Lexicon Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Clinical Update
Lexicon Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Clinical Update
Read more →LXRX▼ -27.4%on this news
Lexicon Voluntarily Withdraws Sotagliflozin New Drug Application and Plans Prompt Resubmission Targeted Early Q2 2022
Lexicon Voluntarily Withdraws Sotagliflozin New Drug Application and Plans Prompt Resubmission Targeted Early Q2 2022
Read more →LXRXLexicon Pharmaceuticals to Host Fourth Quarter 2021 Financial Results Conference Call and Webcast on February 28, 2022
Lexicon Pharmaceuticals to Host Fourth Quarter 2021 Financial Results Conference Call and Webcast on February 28, 2022
Read more →LXRXLexicon Pharmaceuticals Outlines Major Potential Value Drivers for 2022 at 40th Annual J.P. Morgan Healthcare Conference
Lexicon Pharmaceuticals Outlines Major Potential Value Drivers for 2022 at 40th Annual J.P. Morgan Healthcare Conference
Read more →LXRXLexicon Pharmaceuticals to Participate in The 40th Annual J.P. Morgan Healthcare Conference
Lexicon Pharmaceuticals to Participate in The 40th Annual J.P. Morgan Healthcare Conference
Read more →LXRXLexicon Submits New Drug Application for Sotagliflozin for the Treatment of Heart Failure in Adults With Type 2 Diabetes
Lexicon Submits New Drug Application for Sotagliflozin for the Treatment of Heart Failure in Adults With Type 2 Diabetes
Read more →LXRXLexicon Pharmaceuticals to Participate in the Jefferies London Healthcare Conference and the Piper Sandler 33rd Annual Healthcare Conference
Lexicon Pharmaceuticals to Participate in the Jefferies London Healthcare Conference and the Piper Sandler 33rd Annual Healthcare Conference
Read more →LXRXLexicon's Sotagliflozin Demonstrates Benefits in Heart Failure and Blood Glucose Control Across the Full Range of Kidney Function in New Analysis of Clinical Data
Lexicon's Sotagliflozin Demonstrates Benefits in Heart Failure and Blood Glucose Control Across the Full Range of Kidney Function in New Analysis of Clinical Data
Read more →LXRXNew Analysis to be Presented at the American Heart Association Scientific Sessions 2021 Evaluating Cardiovascular Benefits Across Baseline Kidney Function
New Analysis to be Presented at the American Heart Association Scientific Sessions 2021 Evaluating Cardiovascular Benefits Across Baseline Kidney Function
Read more →LXRXLexicon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Clinical Update
Lexicon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Clinical Update
Read more →LXRXLexicon Pharmaceuticals to Host Third Quarter 2021 Financial Results Conference Call and Webcast on November 3, 2021
Lexicon Pharmaceuticals to Host Third Quarter 2021 Financial Results Conference Call and Webcast on November 3, 2021
Read more →LXRXLexicon Pharmaceuticals to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Lexicon Pharmaceuticals to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Read more →LXRXLexicon Welcomes New ESC Heart Failure Treatment Guidelines Establishing SGLT Inhibitors as Standard of Care
Lexicon Welcomes New ESC Heart Failure Treatment Guidelines Establishing SGLT Inhibitors as Standard of Care
Read more →LXRX▲ +11.8%on this news
Lexicon's Sotagliflozin Demonstrates Additional Compelling Benefits in Reducing Cardiovascular Endpoints: Results from Soloist and Scored Trials
Lexicon's Sotagliflozin Demonstrates Additional Compelling Benefits in Reducing Cardiovascular Endpoints: Results from Soloist and Scored Trials
Read more →LXRXCraig Granowitz, M.D., Ph.D. Joins Lexicon as Senior Vice President and Chief Medical Officer
Craig Granowitz, M.D., Ph.D. Joins Lexicon as Senior Vice President and Chief Medical Officer
Read more →LXRXLexicon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical Update
Lexicon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical Update
Read more →LXRX▲ +5%on this newsshared move
Lexicon Pharmaceuticals to Host Second Quarter 2021 Financial Results Conference Call and Webcast on July 30, 2021
Lexicon Pharmaceuticals to Host Second Quarter 2021 Financial Results Conference Call and Webcast on July 30, 2021
Read more →LXRXLexicon Pharmaceuticals Announces Symposium at the American Diabetes Association 81st Scientific Sessions
Lexicon Pharmaceuticals Announces Symposium at the American Diabetes Association 81st Scientific Sessions
Read more →LXRXLexicon Pharmaceuticals to Participate in the 2021 Jefferies Virtual Healthcare Conference
Lexicon Pharmaceuticals to Participate in the 2021 Jefferies Virtual Healthcare Conference
Read more →LXRXLexicon Pharmaceuticals Announces Two Presentations at the American College of Cardiology's 70th Annual Scientific Session
Lexicon Pharmaceuticals Announces Two Presentations at the American College of Cardiology's 70th Annual Scientific Session
Read more →LXRXLexicon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical Update
Lexicon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical Update
Read more →LXRXLexicon Pharmaceuticals to Host First Quarter 2021 Financial Results Conference Call and Webcast on May 6, 2021
Lexicon Pharmaceuticals to Host First Quarter 2021 Financial Results Conference Call and Webcast on May 6, 2021
Read more →LXRXLexicon Pharmaceuticals to Participate in the 20th Annual Needham Virtual Healthcare Conference
Lexicon Pharmaceuticals to Participate in the 20th Annual Needham Virtual Healthcare Conference
Read more →LXRXLexicon Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Clinical Update
Lexicon Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Clinical Update
Read more →LXRXLexicon Pharmaceuticals to Host Fourth Quarter and Full-Year 2020 Financial Results Conference Call and Webcast on March 10, 2021
Lexicon Pharmaceuticals to Host Fourth Quarter and Full-Year 2020 Financial Results Conference Call and Webcast on March 10, 2021
Read more →LXRXLexicon Pharmaceuticals Provides Regulatory Update on Sotagliflozin in Heart Failure
Lexicon Pharmaceuticals Provides Regulatory Update on Sotagliflozin in Heart Failure
Read more →LXRXLexicon Pharmaceuticals to Participate in the 39th Annual J.P. Morgan Healthcare Conference
Lexicon Pharmaceuticals to Participate in the 39th Annual J.P. Morgan Healthcare Conference
Read more →LXRXLexicon Pharmaceuticals Announces Commencement of Dosing in Phase 2 Clinical Study of LX9211 in Post-Herpetic Neuralgia
Lexicon Pharmaceuticals Announces Commencement of Dosing in Phase 2 Clinical Study of LX9211 in Post-Herpetic Neuralgia
Read more →LXRXLexicon Pharmaceuticals Enters Data Collaboration With AC Bioscience
Lexicon Pharmaceuticals Enters Data Collaboration With AC Bioscience
Read more →LXRXLEXICON PHARMACEUTICALS RECEIVES FAST TRACK DESIGNATION FROM THE FDA FOR LX9211 FOR DIABETIC PERIPHERAL NEUROPATHIC PAIN The Woodlands, Texas
LEXICON PHARMACEUTICALS RECEIVES FAST TRACK DESIGNATION FROM THE FDA FOR LX9211 FOR DIABETIC PERIPHERAL NEUROPATHIC PAIN The Woodlands, Texas, December 11, 2020 Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that it has received Fast Track designation from the U.
Read more →LXRXLexicon Pharmaceuticals Receives Fast Track Designation From the FDA for LX9211 for Diabetic Peripheral Neuropathic Pain
Lexicon Pharmaceuticals Receives Fast Track Designation From the FDA for LX9211 for Diabetic Peripheral Neuropathic Pain
Read more →LXRXLexicon Announces Offering of Common Stock
Lexicon Announces Offering of Common Stock
Read more →LXRXLEXICON ANNOUNCES OFFERING OF COMMON STOCK The Woodlands, Texas
LEXICON ANNOUNCES OFFERING OF COMMON STOCK The Woodlands, Texas, December 11, 2020 Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it had entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale, in
Read more →LXRXResults From SOLOIST and SCORED Outcomes Studies Presented at Late-Breaking Science Session of American Heart Association Scientific Sessions and Published in The New England Journal of Medicine
Results From SOLOIST and SCORED Outcomes Studies Presented at Late-Breaking Science Session of American Heart Association Scientific Sessions and Published in The New England Journal of Medicine
Read more →LXRXLexicon Pharmaceuticals to Participate in the Stifel 2020 Virtual Healthcare Conference
Lexicon Pharmaceuticals to Participate in the Stifel 2020 Virtual Healthcare Conference
Read more →LXRXLexicon Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical Update
Lexicon Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical Update
Read more →LXRXLexicon Pharmaceuticals to Host Third Quarter 2020 Financial Results Conference Call and Webcast on October 29, 2020
Lexicon Pharmaceuticals to Host Third Quarter 2020 Financial Results Conference Call and Webcast on October 29, 2020
Read more →LXRXLexicon Pharmaceuticals Reaches Agreements to Exchange Convertible Notes, Reduce Outstanding Indebtedness
Lexicon Pharmaceuticals Reaches Agreements to Exchange Convertible Notes, Reduce Outstanding Indebtedness
Read more →LXRXLexicon Pharmaceuticals Completes the Sale of XERMELO to TerSera Therapeutics
Lexicon Receives $160.4 Million at Closing Eligible for Up to $65 Million in Milestone Payments Plus Mid-Teens Royalties on Net Sales of XERMELO in Biliary Tract Cancer Substantial Debt Reduction with Full Repayment of Secured Loan THE WOODLANDS, Texas, Sept. 08, 2020 (GLOBE N
Read more →LXRXLexicon Pharmaceuticals Announces Commencement of Patient Dosing in RELIEF-DPN-1 Phase 2 Clinical Study of LX9211 in Patients With Diabetic Peripheral Neuropathic Pain
Lexicon Pharmaceuticals Announces Commencement of Patient Dosing in RELIEF-DPN-1 Phase 2 Clinical Study of LX9211 in Patients With Diabetic Peripheral Neuropathic Pain
Read more →LXRXLexicon Pharmaceuticals to Participate in the Citi 15ᵗʰ Annual BioPharma Virtual Conference and the Wells Fargo 2020 Virtual Healthcare Conference
Lexicon Pharmaceuticals to Participate in the Citi 15ᵗʰ Annual BioPharma Virtual Conference and the Wells Fargo 2020 Virtual Healthcare Conference
Read more →LXRXGTCR and TerSera Therapeutics Announce Acquisition of Xermelo
GTCR and TerSera Therapeutics Announce Acquisition of Xermelo
Read more →LXRXLexicon Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides a Business Update
Lexicon Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides a Business Update
Read more →LXRXLexicon Pharmaceuticals Enters Into Agreement With TerSera Therapeutics for the Sale of XERMELO
Lexicon Pharmaceuticals Enters Into Agreement With TerSera Therapeutics for the Sale of XERMELO
Read more →LXRXLexicon Realigns Business Around Research and Development Assets, with Focus on Phase 2 LX9211 Neuropathic Pain Program
Lexicon Realigns Business Around Research and Development Assets, with Focus on Phase 2 LX9211 Neuropathic Pain Program
Read more →LXRXLexicon Pharmaceuticals to Host Second Quarter 2020 Financial Results Conference Call and Webcast on July 30, 2020
THE WOODLANDS, Texas, July 23, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its second quarter 2020 financial results on Thursday, July 30, 2020 before market opens. Management will conduct a conference call and live webcast at 8:00 a.m. ET
Read more →LXRXLexicon Pharmaceuticals Announces Topline Phase 3 Data From Four Phase 3 Sotagliflozin Studies in Type 2 Diabetes
Lexicon Pharmaceuticals Announces Topline Phase 3 Data From Four Phase 3 Sotagliflozin Studies in Type 2 Diabetes
Read more →LXRXLexicon Pharmaceuticals Announces Poster Presentations at the Virtual Cholangiocarcinoma Foundation Annual Conference
Lexicon Pharmaceuticals Announces Poster Presentations at the Virtual Cholangiocarcinoma Foundation Annual Conference
Read more →LXRXLexicon Pharmaceuticals Presents Clinical Data at 80th American Diabetes Association Scientific Sessions
Lexicon Pharmaceuticals Presents Clinical Data at 80th American Diabetes Association Scientific Sessions
Read more →LXRXLexicon Pharmaceuticals to Present at Upcoming Investor Conference
THE WOODLANDS, Texas, May 27, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, President and Chief Executive Officer, will present at the following conference: Jefferies Virtual Healthcare Conference on Tuesday, June 2, 20
Read more →LXRXLexicon Pharmaceuticals Announces Preclinical Efficacy Data on Telotristat Ethyl's Antiproliferative Effects Against Various Cancer Cell Lines
Lexicon Pharmaceuticals Announces Preclinical Efficacy Data on Telotristat Ethyl's Antiproliferative Effects Against Various Cancer Cell Lines
Read more →LXRXLexicon Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides a Business Update
Lexicon Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides a Business Update
Read more →LXRXLexicon Pharmaceuticals to Host First Quarter 2020 Financial Results Conference Call and Webcast On April 27, 2020
THE WOODLANDS, Texas, April 22, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its first quarter 2020 financial results on Monday, April 27, 2020 before market opens. Management will conduct a conference call and live webcast at 8:00 a.m. ET (7
Read more →LXRXLEXICON PHARMACEUTICALS TO HOST VIRTUAL ANNUAL MEETING OF STOCKHOLDERS ON APRIL 23, 2020
THE WOODLANDS, Texas, April 07, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will host its 2020 annual meeting of stockholders in a virtual format only due to the public health impact of the coronavirus pandemic and to prioritize the health and well-being
Read more →LXRXLEXICON PHARMACEUTICALS PROVIDES AN UPDATE ON THE SOTAGLIFLOZIN TYPE 2 DIABETES PROGRAM
THE WOODLANDS, Texas, March 19, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today provided an update on its ZynquistaTM (sotagliflozin) program in type 2 diabetes, heart failure and chronic kidney disease. The company will close out early the two long-t
Read more →LXRXLEXICON PHARMACEUTICALS ANNOUNCES ADDITIONAL DATA ON TELOTRISTAT ETHYL’S ANTIPROLIFERATIVE EFFECTS IN PATIENTS WITH CARCINOID SYNDROME
THE WOODLANDS, Texas, March 13, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today additional data on XERMELO’s® (telotristat ethyl) antiproliferative effects in patients with carcinoid syndrome that were presented at the European Neuroendocrin
Read more →LXRXLexicon Pharmaceuticals Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides a Business Update
Lexicon Pharmaceuticals Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides a Business Update
Read more →LXRXLexicon Pharmaceuticals to Host Fourth Quarter and Full-Year 2019 Financial Results Conference Call and Webcast on March 12, 2020
Lexicon Pharmaceuticals to Host Fourth Quarter and Full-Year 2019 Financial Results Conference Call and Webcast on March 12, 2020
Read more →LXRXLexicon Pharmaceuticals Announces Real-World Data on Telotristat Ethyl’s Antiproliferative Effects in Patients With Carcinoid Syndrome
THE WOODLANDS, Texas, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today real-world data on XERMELO’s® (telotristat ethyl) antiproliferative effects in patients with carcinoid syndrome that were presented at the American Society for Cl
Read more →LXRXLexicon Pharmaceuticals Announces Poster Presentation at the ASCO 2020 Gastrointestinal Cancers Symposium
THE WOODLANDS, Texas, Jan. 20, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that data from a poster highlighting XERMELO® (telotristat ethyl) will be presented at the American Society for Clinical Oncology (ASCO) 2020 Symposium (January 2
Read more →LXRXLexicon Pharmaceuticals Announces Topline Phase 3 Data for Sotagliflozin in Type 2 Diabetes
Lexicon Pharmaceuticals Announces Topline Phase 3 Data for Sotagliflozin in Type 2 Diabetes
Read more →LXRXLexicon Pharmaceuticals Announces Positive Topline Phase 1 Data for LX9211
THE WOODLANDS, Texas, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced positive topline data from the Phase 1 multiple ascending dose study of LX9211, a potent oral small molecule inhibitor of adaptor associated kinase 1 (AAK1), in d
Read more →LXRXLexicon Pharmaceuticals Completes Safety Review of Initial Safety Run-in Cohort of TELE-ABC Study, a Phase 2 Clinical Study of Telotristat Ethyl in Biliary Tract Cancer
THE WOODLANDS, Texas, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today the completion of a safety review of the initial run-in cohort of the Telotristat Ethyl for Advanced Biliary Tract Cancer, or TELE-ABC, study, which is a Phase 2
Read more →LXRXLexicon Pharmaceuticals Receives Formal Dispute Resolution Request Decision From FDA's Office of New Drugs for Sotagliflozin in Type 1 Diabetes
Lexicon Pharmaceuticals Receives Formal Dispute Resolution Request Decision From FDA's Office of New Drugs for Sotagliflozin in Type 1 Diabetes
Read more →LXRXLexicon Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides a Business Update
Lexicon Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides a Business Update
Read more →LXRXLexicon Pharmaceuticals to Host Third Quarter 2019 Financial Results Conference Call and Webcast on November 7, 2019
THE WOODLANDS, Texas, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its third quarter 2019 financial results on Thursday, November 7, 2019 before market opens. Management will conduct a conference call and live webcast at 8:00 a.m. E
Read more →LXRXLexicon Pharmaceuticals Announces Poster Presentations at the NANETS Annual Multidisciplinary NET Medical Symposium
THE WOODLANDS, Texas, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that data from five posters highlighting XERMELO® (telotristat ethyl) will be presented at the upcoming North American Neuroendocrine Tumor Society Annual Multidi
Read more →LXRXLexicon Pharmaceuticals to Present Sotagliflozin Clinical Data at the European Association for the Study of Diabetes 55th Annual Meeting
THE WOODLANDS, Texas, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that clinical data for ZynquistaTM (sotagliflozin) will be presented at the upcoming European Association for the Study of Diabetes (EASD) 55th annual meeting (S
Read more →LXRXLexicon Pharmaceuticals Announces Termination of Alliance and Settlement With Sanofi
Lexicon Pharmaceuticals Announces Termination of Alliance and Settlement With Sanofi
Read more →LXRXLexicon Pharmaceuticals To Present At Upcoming Investor Conference
THE WOODLANDS, Texas, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeffrey L. Wade, J.D., Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer, will present at the following conference:
Read more →LXRXLexicon Pharmaceuticals Announces Publication of Positive Data for Zynquista™ (Sotagliflozin) on Cardiorenal Clinical Biomarkers in Adults With Type 1 Diabetes
Lexicon Pharmaceuticals Announces Publication of Positive Data for Zynquista™ (Sotagliflozin) on Cardiorenal Clinical Biomarkers in Adults With Type 1 Diabetes
Read more →LXRXLexicon Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides a Business Update
Lexicon Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides a Business Update
Read more →LXRXLexicon Pharmaceuticals Announces Date Change for Second Quarter 2019 Financial Results Conference Call and Webcast to July 31, 2019
THE WOODLANDS, Texas, July 30, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that it has changed the date of its previously announced earnings release, conference call and webcast and will now release financial results for the second quart
Read more →LXRXLexicon Pharmaceuticals Provides Preliminary Update for Zynquista™ (Sotagliflozin) Type 2 Diabetes Phase 3 Program
Lexicon Pharmaceuticals Provides Preliminary Update for Zynquista™ (Sotagliflozin) Type 2 Diabetes Phase 3 Program
Read more →LXRXLexicon Pharmaceuticals to Host Second Quarter 2019 Financial Results Conference Call and Webcast on August 1, 2019
THE WOODLANDS, Texas, July 25, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its second quarter 2019 financial results on Thursday, August 1, 2019 before market opens. Management will conduct a conference call and live webcast at 8:00 a.m. ED
Read more →LXRXLexicon Pharmaceuticals to Present New Clinical Data at 79th American Diabetes Association Scientific Sessions
THE WOODLANDS, Texas, June 04, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced new analyses of clinical data for sotagliflozin will be presented at the upcoming 79th American Diabetes Association (ADA) Scientific Sessions in San Francisco, C
Read more →LXRXLexicon Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides a Business Update
Lexicon Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides a Business Update
Read more →LXRXLexicon Pharmaceuticals to Host First Quarter 2019 Financial Results Conference Call and Webcast on May 1, 2019
THE WOODLANDS, Texas, April 25, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its first quarter 2019 financial results on Wednesday, May 1, 2019 before market opens. Management will conduct a conference call and live webcast at 8:00 a.m. EDT
Read more →LXRXFDA Issues Complete Response Letter for Zynquista™ (sotagliflozin)
FDA Issues Complete Response Letter for Zynquista™ (sotagliflozin)
Read more →LXRXLexicon Pharmaceuticals to Host Conference Call and Webcast Today, March 22, 2019 to Provide a Regulatory Update on Sotagliflozin in Type 1 Diabetes
Lexicon Pharmaceuticals to Host Conference Call and Webcast Today, March 22, 2019 to Provide a Regulatory Update on Sotagliflozin in Type 1 Diabetes
Read more →LXRXLexicon Pharmaceuticals Announces Dosing of First Patient in TELE-ABC Study, a Phase 2a Clinical Study of Telotristat Ethyl in Biliary Tract Cancer
THE WOODLANDS, Texas, March 15, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today dosing of the first patient in the Telotristat Ethyl for Advanced Biliary Tract Cancer, or TELE-ABC, study, which is a Phase 2a clinical study of telotristat eth
Read more →LXRXLexicon Pharmaceuticals Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides a Business Update
Lexicon Pharmaceuticals Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides a Business Update
Read more →LXRXLexicon Pharmaceuticals to Host Fourth Quarter and Full-Year 2018 Financial Results Conference Call and Webcast on March 13, 2019
THE WOODLANDS, Texas, March 11, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its fourth quarter and full-year 2018 financial results on Wednesday, March 13, 2019 before market opens. Management will conduct a conference call and live webcast
Read more →LXRXLexicon Pharmaceuticals Announces Poster Presentations at the 16th Annual ENETS Conference
THE WOODLANDS, Texas, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that data from two posters highlighting XERMELO® (telotristat ethyl) will be presented at the upcoming 16th Annual European Neuroendocrine Tumor Society Conferenc
Read more →LXRXLexicon Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Review Sotagliflozin New Drug Application for the Treatment of Type 1 Diabetes
Lexicon Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Review Sotagliflozin New Drug Application for the Treatment of Type 1 Diabetes
Read more →LXRXFDA Advisory Committee Votes on Zynquista™ (sotagliflozin) as Treatment for Adults With Type 1 Diabetes
FDA Advisory Committee Votes on Zynquista™ (sotagliflozin) as Treatment for Adults With Type 1 Diabetes
Read more →LXRXLexicon Pharmaceuticals to Host Conference Call and Webcast on January 17, 2019 to Discuss Outcome of FDA Advisory Committee Meeting for Sotagliflozin in Type 1 Diabetes
THE WOODLANDS, Texas, Jan. 17, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that management will conduct a conference call and live webcast on Thursday, January 17, 2019, at 7:00 p.m. EST (6:00 p.m. CST) to discuss the outcome of the U.S.
Read more →LXRXLexicon Pharmaceuticals Announces Topline Phase 1 Clinical Results for LX2761 in Diabetes
THE WOODLANDS, Texas, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced topline results from Phase 1 clinical studies of LX2761, an oral sodium-glucose cotransporter type 1 (SGLT1) inhibitor in development for the treatment of diabete
Read more →LXRXLexicon Pharmaceuticals Announces Positive Topline Clinical Data for LX9211
THE WOODLANDS, Texas, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced positive topline results from its Phase 1a study of LX9211, a potent oral small molecule inhibitor of adaptor associated kinase 1, or AAK1, in development for the
Read more →LXRXLexicon Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides a Business Update
THE WOODLANDS, Texas, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results and provided a business update for the three months ended September 30, 2018. “In the third quarter, we and our collaborator, Sanofi, have been
Read more →LXRXLexicon Pharmaceuticals to Host Third Quarter 2018 Financial Results Conference Call and Webcast on November 1, 2018
THE WOODLANDS, Texas, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its third quarter 2018 financial results on Thursday, November 1, 2018 before market opens. Management will conduct a conference call and live webcast at 8:00 a.m. E
Read more →LXRXLexicon Pharmaceuticals and Ipsen Biopharmaceuticals Canada Inc. Announce Health Canada Approval of XERMELO (Telotristat Ethyl) for the Treatment of Refractory Carcinoid Syndrome Diarrhea in Combination With Somatostatin Analog Therapy
Approval Enables Availability of First-in-Class Oral Tryptophan Hydroxylase Inhibitor that Sustains Improvement of Carcinoid Syndrome Diarrhea in Adults Inadequately Controlled by Somatostatin Analogs Alone THE WOODLANDS, Texas and CAMBRIDGE, Mass., Oct. 16, 2018 (GLOBE NEWSWIRE
Read more →LXRXLexicon Pharmaceuticals to Present Sotagliflozin Clinical Data at the European Association for the Study of Diabetes 54th Annual Meeting
THE WOODLANDS, Texas, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that clinical data for sotagliflozin will be presented at the upcoming European Association for the Study of Diabetes (EASD) 54th annual meeting (October 1-5, Be
Read more →LXRXLexicon Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides a Business Update
XERMELO® (telotristat ethyl) Quarterly U.S. Net Sales of $6.0 Million, Up 65% from Prior Year Quarter and 11% Quarter-Over-Quarter Filings for Regulatory Approval of Sotagliflozin in Type 1 Diabetes Accepted THE WOODLANDS, Texas, July 30, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharma
Read more →LXRXLexicon Pharmaceuticals to Host First Quarter 2018 Financial Results Conference Call and Webcast on July 30, 2018
THE WOODLANDS, Texas, July 23, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), will release its second quarter 2018 financial results on Monday, July 30, 2018 before market opens. Management will conduct a conference call and live webcast at 8:00 a.m. EDT (7
Read more →LXRXLexicon Pharmaceuticals Announces Positive 52-Week Results From Sotagliflozin inTandem1 Study Presented at ADA 2018 and Published in Diabetes Care
Lexicon Pharmaceuticals Announces Positive 52-Week Results From Sotagliflozin inTandem1 Study Presented at ADA 2018 and Published in Diabetes Care
Read more →LXRXLexicon Pharmaceuticals to Present New Clinical Data at 78th American Diabetes Association Scientific Sessions
THE WOODLANDS, Texas, June 18, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), today announced that new clinical data for sotagliflozin will be presented at the upcoming 78th American Diabetes Association (ADA) Scientific Sessions in Orlando, FL, from June 2
Read more →LXRXFDA to review Zynquista™ (sotagliflozin) as potential treatment for type 1 diabetes
FDA to review Zynquista™ (sotagliflozin) as potential treatment for type 1 diabetes
Read more →LXRXLexicon Pharmaceuticals Announces Publication of New XERMELO® (Telotristat Ethyl) Data in Clinical Therapeutics
Lexicon Pharmaceuticals Announces Publication of New XERMELO® (Telotristat Ethyl) Data in Clinical Therapeutics
Read more →LXRXLexicon Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides a Business Update
XERMELO® (telotristat ethyl) Quarterly U.S. Net Sales of $5.4 Million Filings Submitted for Regulatory Approval of Sotagliflozin in Type 1 Diabetes THE WOODLANDS, Texas, May 03, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), today reported financial resul
Read more →LXRXLexicon Pharmaceuticals to Host First Quarter 2018 Financial Results Conference Call and Webcast on May 3, 2018
THE WOODLANDS, Texas, April 26, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), will release its first quarter 2018 financial results on Thursday, May 3, 2018 before market opens. Management will conduct a conference call and live webcast at 8:00 a.m. EDT (7
Read more →LXRXLexicon Pharmaceuticals to Highlight Pipeline Progress at R&d Day on April 10, 2018
THE WOODLANDS, Texas, April 03, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), announced today that it will host its 2018 Research & Development (R&D) Day on Tuesday, April 10, 2018, from 8:30 a.m. to 11:30 a.m. EDT (7:30 a.m. to 10:30 a.m. CDT) in New York
Read more →LXRXLexicon Pharmaceuticals Announces EMA Acceptance of Marketing Authorization Application (MAA) for Sotagliflozin to Treat Adults With Type 1 Diabetes
THE WOODLANDS, Texas, March 29, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) filed by Lexicon’s collaborator, Sanofi, for sotagliflozin, an
Read more →LXRXLexicon Pharmaceuticals Announces Regulatory Submissions for Sotagliflozin to Treat Adults With Type 1 Diabetes
New Drug Application Submitted to U.S. Food and Drug Administration Marketing Authorization Application Submitted to European Medicines Agency THE WOODLANDS, Texas, March 26, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), today announced that its collabor
Read more →LXRXLexicon Pharmaceuticals Announces Poster Presentation at the 15th Annual ENETS Conference
Lexicon Pharmaceuticals Announces Poster Presentation at the 15th Annual ENETS Conference
Read more →LXRXLexicon Pharmaceuticals to Present at Upcoming Investor Conferences
THE WOODLANDS, Texas, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX) today announced that Jeffrey L. Wade, J.D., Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer, will present at the following conferences:
Read more →LXRXLexicon Pharmaceuticals Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides a Business Update
XERMELO® (telotristat ethyl) U.S. Net Sales Since March 2017 Launch Reach $15.1 Million Regulatory Filings for Sotagliflozin in Patients with Type 1 Diabetes Expected in First Quarter of 2018 THE WOODLANDS, Texas, Feb. 22, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc.
Read more →LXRXLexicon Pharmaceuticals to Host Fourth Quarter and Full-Year 2017 Financial Results Conference Call and Webcast on February 22, 2018
THE WOODLANDS, Texas, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), will release its fourth quarter and full-year 2017 financial results on Thursday, February 22, 2018 before market opens. Management will conduct a conference call and live webcast
Read more →LXRXLexicon Pharmaceuticals Announces Poster Presentation at ASCO GI
THE WOODLANDS, Texas, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), announced today that data from a poster highlighting XERMELO® (telotristat ethyl) will be presented at the upcoming 2018 American Society of Clinical Oncology’s Gastrointestinal C
Read more →LXRXLexicon Pharmaceuticals Secures Up To $200 Million Non-Dilutive Term Loan Financing
THE WOODLANDS, Texas, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX) today announced that it has entered into a definitive term loan agreement with BioPharma Credit PLC and BioPharma Credit Investments IV Sub LP, investment funds managed by Pharmako
Read more →LXRXLexicon Pharmaceuticals Reports Third Quarter 2017 Financial Results And Provides A Business Update
Lexicon Pharmaceuticals Reports Third Quarter 2017 Financial Results And Provides A Business Update
Read more →LXRXLexicon Pharmaceuticals To Host Third Quarter 2017 Financial Results Conference Call And Webcast On November 8, 2017
Lexicon Pharmaceuticals To Host Third Quarter 2017 Financial Results Conference Call And Webcast On November 8, 2017
Read more →LXRXLexicon Pharmaceuticals To Present At Upcoming Investor Conferences
Lexicon Pharmaceuticals To Present At Upcoming Investor Conferences
Read more →LXRXLexicon Pharmaceuticals Initiates Patient Dosing In A Phase 1 Study Of LX9211
Lexicon Pharmaceuticals Initiates Patient Dosing In A Phase 1 Study Of LX9211
Read more →LXRXEuropean Commission Approves XERMELO® (Telotristat Ethyl) For The Treatment Of Carcinoid Syndrome Diarrhea
European Commission Approves XERMELO® (Telotristat Ethyl) For The Treatment Of Carcinoid Syndrome Diarrhea
Read more →LXRXLexicon Pharmaceuticals To Present At The 2017 Cantor Fitzgerald Global Healthcare Conference
Lexicon Pharmaceuticals To Present At The 2017 Cantor Fitzgerald Global Healthcare Conference
Read more →LXRXNew England Journal Of Medicine Publishes Data From Phase 3 inTandem3 Study Of Sotagliflozin
New England Journal Of Medicine Publishes Data From Phase 3 inTandem3 Study Of Sotagliflozin
Read more →LXRXLexicon Pharmaceuticals Reports Positive Pooled Continuous Glucose Monitoring Data
Lexicon Pharmaceuticals Reports Positive Pooled Continuous Glucose Monitoring Data
Read more →LXRXLexicon Pharmaceuticals Announces Four Data Presentations At The European Society Of Medical Oncology 2017 Congress
Lexicon Pharmaceuticals Announces Four Data Presentations At The European Society Of Medical Oncology 2017 Congress
Read more →LXRXLexicon Pharmaceuticals To Present At The Bank Of America Merrill Lynch 2017 Global Healthcare Conference
Lexicon Pharmaceuticals To Present At The Bank Of America Merrill Lynch 2017 Global Healthcare Conference
Read more →LXRXLexicon Pharmaceuticals to Present New Clinical Data at the European Association for the Study of Diabetes 53rd Annual Meeting
Lexicon Pharmaceuticals to Present New Clinical Data at the European Association for the Study of Diabetes 53rd Annual Meeting
Read more →LXRXLexicon Pharmaceuticals Reports Additional Positive Data From Pivotal Phase 3 inTandem2 Study
Lexicon Pharmaceuticals Reports Additional Positive Data From Pivotal Phase 3 inTandem2 Study
Read more →LXRXLexicon Pharmaceuticals To Present At 2017 Wedbush PacGrow Healthcare Conference
Lexicon Pharmaceuticals To Present At 2017 Wedbush PacGrow Healthcare Conference
Read more →LXRXLexicon Pharmaceuticals Reports Second Quarter 2017 Financial Results And Provides A Business Update
Lexicon Pharmaceuticals Reports Second Quarter 2017 Financial Results And Provides A Business Update
Read more →LXRXLexicon Pharmaceuticals Announces Opt-In Decision For U.S. Co-Promotion Of Sotagliflozin With Sanofi
Lexicon Pharmaceuticals Announces Opt-In Decision For U.S. Co-Promotion Of Sotagliflozin With Sanofi
Read more →LXRXLexicon Pharmaceuticals To Host Second Quarter 2017 Financial Results Conference Call And Webcast
Lexicon Pharmaceuticals To Host Second Quarter 2017 Financial Results Conference Call And Webcast
Read more →LXRXLexicon Collaborator Ipsen Receives Positive CHMP Opinion For Xermelo®
Lexicon Collaborator Ipsen Receives Positive CHMP Opinion For Xermelo®
Read more →LXRXNCCN Guidelines For Neuroendocrine Tumors Include XERMELO In Combination With Somatostatin Analog Therapy
NCCN Guidelines For Neuroendocrine Tumors Include XERMELO In Combination With Somatostatin Analog Therapy
Read more →LXRXSotagliflozin Data from Pivotal inTandem1 and inTandem2 Studies Presented at ADA 2017
Sotagliflozin Data from Pivotal inTandem1 and inTandem2 Studies Presented at ADA 2017
Read more →LXRXLexicon Pharmaceuticals Reports Positive Top-Line Results In Phase 3 inTandem3 Study For Sotagliflozin
Lexicon Pharmaceuticals Reports Positive Top-Line Results In Phase 3 inTandem3 Study For Sotagliflozin
Read more →LXRXLexicon Pharmaceuticals To Present New Clinical Data At 77th American Diabetes Association Scientific Sessions
Lexicon Pharmaceuticals To Present New Clinical Data At 77th American Diabetes Association Scientific Sessions
Read more →LXRXLexicon Pharmaceuticals Reports Additional Positive Data From Pivotal InTandem1 Phase 3 Study
Lexicon Pharmaceuticals Reports Additional Positive Data From Pivotal InTandem1 Phase 3 Study
Read more →LXRXLexicon Pharmaceuticals To Present At The Bank Of America Merrill Lynch 2017 Healthcare Conference
Lexicon Pharmaceuticals To Present At The Bank Of America Merrill Lynch 2017 Healthcare Conference
Read more →LXRXLexicon Pharmaceuticals Reports First Quarter 2017 Financial Results And Provides A Business Update
Lexicon Pharmaceuticals Reports First Quarter 2017 Financial Results And Provides A Business Update
Read more →LXRXLexicon Pharmaceuticals To Host First Quarter 2017 Financial Results Conference Call And Webcast On May 2, 2017
Lexicon Pharmaceuticals To Host First Quarter 2017 Financial Results Conference Call And Webcast On May 2, 2017
Read more →LXRXLexicon To Present At The 16th Annual Needham Healthcare Conference
Lexicon To Present At The 16th Annual Needham Healthcare Conference
Read more →LXRXLexicon To Present At The Barclays Global Healthcare Conference
Lexicon To Present At The Barclays Global Healthcare Conference
Read more →LXRXLexicon To Present At The Cowen And Company 37th Annual Healthcare Conference
Lexicon To Present At The Cowen And Company 37th Annual Healthcare Conference
Read more →LXRXLexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2016 Fourth Quarter And Full Year Financial Results
Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2016 Fourth Quarter And Full Year Financial Results
Read more →LXRXLexicon To Report Fourth Quarter And Year End 2016 Financial Results On March 3, 2017
Lexicon To Report Fourth Quarter And Year End 2016 Financial Results On March 3, 2017
Read more →LXRXFDA Approves Lexicon Drug XERMELO™ (telotristat ethyl) 250 mg As First And Only Oral Treatment For Carcinoid Syndrome Diarrhea In Cancer Patients With Metastatic Neuroendocrine Tumors
FDA Approves Lexicon Drug XERMELO™ (telotristat ethyl) 250 mg As First And Only Oral Treatment For Carcinoid Syndrome Diarrhea In Cancer Patients With Metastatic Neuroendocrine Tumors
Read more →LXRXLexicon To Present At The Leerink Partners 6th Annual Global Healthcare Conference
Lexicon To Present At The Leerink Partners 6th Annual Global Healthcare Conference
Read more →LXRXLexicon Begins Phase 1 Clinical Trial Of Locally-acting SGLT1 Inhibitor, LX2761, For Potential Treatment Of Diabetes
Lexicon Begins Phase 1 Clinical Trial Of Locally-acting SGLT1 Inhibitor, LX2761, For Potential Treatment Of Diabetes
Read more →LXRXLexicon To Present At The 35th Annual J.P. Morgan Healthcare Conference
Lexicon To Present At The 35th Annual J.P. Morgan Healthcare Conference
Read more →LXRXLexicon Reports Positive Top-line Results In Second Pivotal Phase 3 Study For Sotagliflozin In Patients With Type 1 Diabetes
Lexicon Reports Positive Top-line Results In Second Pivotal Phase 3 Study For Sotagliflozin In Patients With Type 1 Diabetes
Read more →LXRXLexicon Announces The Establishment Of The Commercial Leadership Team For Telotristat Ethyl
Lexicon Announces The Establishment Of The Commercial Leadership Team For Telotristat Ethyl
Read more →LXRXLexicon To Present At The Stifel 2016 Healthcare Conference And The Jefferies 2016 Global Healthcare Conference
Lexicon To Present At The Stifel 2016 Healthcare Conference And The Jefferies 2016 Global Healthcare Conference
Read more →LXRXLexicon Pharmaceuticals Acquires Exclusive Rights To Development Candidate For Neuropathic Pain From Its Alliance With Bristol-Myers Squibb
Lexicon Pharmaceuticals Acquires Exclusive Rights To Development Candidate For Neuropathic Pain From Its Alliance With Bristol-Myers Squibb
Read more →LXRXLexicon Announces Publication Of TELESTAR Study Results For Telotristat Ethyl In The Journal Of Clinical Oncology
Lexicon Announces Publication Of TELESTAR Study Results For Telotristat Ethyl In The Journal Of Clinical Oncology
Read more →LXRXLexicon Reports Positive Top-Line Results In Phase 2 Dose-Ranging Study For Sotagliflozin In Patients With Type 1 Diabetes
Lexicon Reports Positive Top-Line Results In Phase 2 Dose-Ranging Study For Sotagliflozin In Patients With Type 1 Diabetes
Read more →LXRXLexicon To Report Third Quarter 2016 Financial Results On November 1, 2016
Lexicon To Report Third Quarter 2016 Financial Results On November 1, 2016
Read more →LXRXLexicon Pharmaceuticals Announces Agreement To Buy Out Remaining Obligations To Symphony Icon
Lexicon Pharmaceuticals Announces Agreement To Buy Out Remaining Obligations To Symphony Icon
Read more →LXRXTelecast Data Presented At The 2016 North American Neuroendocrine Tumor Society Annual Symposium
Telecast Data Presented At The 2016 North American Neuroendocrine Tumor Society Annual Symposium
Read more →LXRXFDA Extends PDUFA Date For Telotristat Etiprate For The Treatment Of Carcinoid Syndrome
FDA Extends PDUFA Date For Telotristat Etiprate For The Treatment Of Carcinoid Syndrome
Read more →LXRXLexicon Reports Positive Top-Line Results In Pivotal Phase 3 Study For Sotagliflozin In Patients With Type 1 Diabetes
Lexicon Reports Positive Top-Line Results In Pivotal Phase 3 Study For Sotagliflozin In Patients With Type 1 Diabetes
Read more →LXRXLexicon To Present At The Bank Of America Merrill Lynch Global Health Care Conference
Lexicon To Present At The Bank Of America Merrill Lynch Global Health Care Conference
Read more →LXRXLexicon To Present At The 2016 Wedbush PacGrow Healthcare Conference
Lexicon To Present At The 2016 Wedbush PacGrow Healthcare Conference
Read more →LXRXLexicon To Report Second Quarter 2016 Financial Results On August 4, 2016
Lexicon To Report Second Quarter 2016 Financial Results On August 4, 2016
Read more →LXRXLexicon Announces The Validation By The European Medicine Agency Of The Marketing Authorization Application For Telotristat Etiprate For The Treatment Of Carcinoid Syndrome
Lexicon Announces The Validation By The European Medicine Agency Of The Marketing Authorization Application For Telotristat Etiprate For The Treatment Of Carcinoid Syndrome
Read more →LXRXLexicon To Present At The Cantor Fitzgerald Healthcare Conference
Lexicon To Present At The Cantor Fitzgerald Healthcare Conference
Read more →LXRXLexicon To Present At The Jefferies 2016 Healthcare Conference
Lexicon To Present At The Jefferies 2016 Healthcare Conference
Read more →LXRXLexicon Announces The Launch Of Aboutcarcinoid.com To Provide Carcinoid Syndrome Disease Education To Patients, Caregivers And Physicians
Lexicon Announces The Launch Of Aboutcarcinoid.com To Provide Carcinoid Syndrome Disease Education To Patients, Caregivers And Physicians
Read more →LXRXLexicon Announces FDA Priority Review Of New Drug Application For Telotristat Etiprate For The Treatment Of Carcinoid Syndrome
Lexicon Announces FDA Priority Review Of New Drug Application For Telotristat Etiprate For The Treatment Of Carcinoid Syndrome
Read more →LXRXPraveen Tyle, Ph.D. Joins Lexicon As Executive Vice President Of Research And Development
Praveen Tyle, Ph.D. Joins Lexicon As Executive Vice President Of Research And Development
Read more →LXRXLexicon To Present At The Bank Of America Merrill Lynch 2016 Health Care Conference
Lexicon To Present At The Bank Of America Merrill Lynch 2016 Health Care Conference
Read more →LXRXLexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2016 First Quarter Financial Results
Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2016 First Quarter Financial Results
Read more →LXRXLexicon To Report First Quarter 2016 Financial Results On May 3, 2016
Lexicon To Report First Quarter 2016 Financial Results On May 3, 2016
Read more →LXRXLexicon To Present At The 15th Annual Needham Healthcare Conference
Lexicon To Present At The 15th Annual Needham Healthcare Conference
Read more →LXRXLexicon Submits New Drug Application To FDA For Telotristat Etiprate For The Treatment Of Carcinoid Syndrome
Lexicon Submits New Drug Application To FDA For Telotristat Etiprate For The Treatment Of Carcinoid Syndrome
Read more →LXRXLexicon Announces Telotristat Etiprate Data To Be Presented At European Neuroendocrine Tumor Society Conference
Lexicon Announces Telotristat Etiprate Data To Be Presented At European Neuroendocrine Tumor Society Conference
Read more →LXRXLexicon To Present At The 36th Annual Cowen Healthcare Conference
Lexicon To Present At The 36th Annual Cowen Healthcare Conference
Read more →LXRXLexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2015 Fourth Quarter And Full Year Financial Results
Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2015 Fourth Quarter And Full Year Financial Results
Read more →LXRXLexicon To Report Fourth Quarter And Year End 2015 Financial Results On March 1, 2016
Lexicon To Report Fourth Quarter And Year End 2015 Financial Results On March 1, 2016
Read more →LXRXLexicon To Present At The 34th Annual J.P. Morgan Healthcare Conference
Lexicon To Present At The 34th Annual J.P. Morgan Healthcare Conference
Read more →LXRXLexicon To Present At The Oppenheimer 26th Annual Healthcare Conference
Lexicon To Present At The Oppenheimer 26th Annual Healthcare Conference
Read more →LXRXTelotristat Etiprate Achieves Positive Top-Line Results In Second Phase 3 Clinical Trial
Telotristat Etiprate Achieves Positive Top-Line Results In Second Phase 3 Clinical Trial
Read more →LXRXLexicon To Present At The Stifel 2015 Healthcare Conference And The Jefferies 2015 Global Healthcare Conference
Lexicon To Present At The Stifel 2015 Healthcare Conference And The Jefferies 2015 Global Healthcare Conference
Read more →LXRXLexicon Pharmaceuticals Reports 3rd Quarter Financial Results And Discusses Collaboration With Sanofi For Sotagliflozin
Lexicon Pharmaceuticals Reports 3rd Quarter Financial Results And Discusses Collaboration With Sanofi For Sotagliflozin
Read more →LXRXLexicon To Report Third Quarter 2015 Financial Results On November 6, 2015
Lexicon To Report Third Quarter 2015 Financial Results On November 6, 2015
Read more →LXRXCancer Patients Treated With Lexicon's Telotristat Etiprate Report Improved Function And Well-Being
Cancer Patients Treated With Lexicon's Telotristat Etiprate Report Improved Function And Well-Being
Read more →LXRXLexicon Announces Telotristat Etiprate Data To Be Presented At North American Neuroendocrine Tumor Society Annual Symposium
Lexicon Announces Telotristat Etiprate Data To Be Presented At North American Neuroendocrine Tumor Society Annual Symposium
Read more →LXRXLexicon's Telotristat Etiprate Shows Clinical Benefit In Treating Carcinoid Syndrome In Cancer Patients When Added To Standard Of Care
Lexicon's Telotristat Etiprate Shows Clinical Benefit In Treating Carcinoid Syndrome In Cancer Patients When Added To Standard Of Care
Read more →LXRXMedia Alert: Lexicon To Discuss Complete Results Of Pivotal Phase 3 TELESTAR Study
Media Alert: Lexicon To Discuss Complete Results Of Pivotal Phase 3 TELESTAR Study
Read more →LXRXLexicon Announces Sotagliflozin Data To Be Presented At European Association For The Study Of Diabetes
Lexicon Announces Sotagliflozin Data To Be Presented At European Association For The Study Of Diabetes
Read more →LXRXLexicon Announces Telotristat Etiprate Data To Be Presented At European Cancer Congress
Lexicon Announces Telotristat Etiprate Data To Be Presented At European Cancer Congress
Read more →LXRXLEXICON PHARMACEUTICALS REPORTS 2 nd QUARTER FINANCIAL RESULTS, PROVIDES CLINICAL PIPELINE UPDATE Pivotal Phase 3 trial for telotristat etiprate in carcinoid syndrome meets primary endpoint Enrollment progressing in pivo
LEXICON PHARMACEUTICALS REPORTS 2nd QUARTER FINANCIAL RESULTS, PROVIDES CLINICAL PIPELINE UPDATE Conference Call and Webcast TODAY, August 7, at 8:30 a.m. Eastern Time The Woodlands, Texas, August 7, 2015 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial
Read more →LXRXLexicon Announces Presentation Of Manuscript At The American Diabetes Association Diabetes Care Symposium
Lexicon Announces Presentation Of Manuscript At The American Diabetes Association Diabetes Care Symposium
Read more →LXRXLexicon To Present At The Jefferies 2015 Healthcare Conference
Lexicon To Present At The Jefferies 2015 Healthcare Conference
Read more →LXRXLexicon Announces Selection Of Manuscript To Be Presented At The American Diabetes Association Diabetes Care Symposium
Lexicon Announces Selection Of Manuscript To Be Presented At The American Diabetes Association Diabetes Care Symposium
Read more →LXRXLexicon to Present at the Bank of America Merrill Lynch 2015 Health Care Conference
Lexicon to Present at the Bank of America Merrill Lynch 2015 Health Care Conference
Read more →LXRXLexicon Announces One For Seven Reverse Stock Split Effective May 20, 2015
Lexicon Announces One For Seven Reverse Stock Split Effective May 20, 2015
Read more →LXRXLEXICON PHARMACEUTICALS PROVIDES CLINICAL PIPELINE UPDATE AND REPORTS 2015 FIRST QUARTER FINANCIAL RESULTS Conference Call and Webcast at 5:00 p.m. Eastern Time The Woodlands, Texas
LEXICON PHARMACEUTICALS PROVIDES CLINICAL PIPELINE UPDATE AND REPORTS 2015 FIRST QUARTER FINANCIAL RESULTS Conference Call and Webcast at 5:00 p.m. Eastern Time The Woodlands, Texas, April 29, 2015 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company foc
Read more →LXRXLexicon To Report First Quarter 2015 Financial Results On April 29, 2015
Lexicon To Report First Quarter 2015 Financial Results On April 29, 2015
Read more →LXRXLexicon Pharmaceuticals and Bristol-Myers Squibb Select Development Candidate for Neuropathic Pain in Neuroscience Drug Discovery and Development Alliance
Lexicon Pharmaceuticals and Bristol-Myers Squibb Select Development Candidate for Neuropathic Pain in Neuroscience Drug Discovery and Development Alliance
Read more →LXRXLexicon To Present At Needham & Company's 14th Annual Healthcare Conference
Lexicon To Present At Needham & Company's 14th Annual Healthcare Conference
Read more →LXRXLexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) to Ring The Nasdaq Stock Market Closing Bell
ADVISORY, Apr. 07, 2015 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), a biopharmaceutical company focused on developing breakthrough treatments for human disease, will visit the Nasdaq MarketSite in Times Square. In honor of the occasion, Lonnel Coats, Presid
Read more →LXRXLexicon Pharmaceuticals Announces First Patient Screened In Pivotal Phase 3 Clinical Trial Of Sotagliflozin
Lexicon Pharmaceuticals Announces First Patient Screened In Pivotal Phase 3 Clinical Trial Of Sotagliflozin
Read more →LXRXLexicon and Ipsen Expand Their Licensing and Commercialization Agreement for Telotristat Etiprate to Include Canada
Lexicon and Ipsen Expand Their Licensing and Commercialization Agreement for Telotristat Etiprate to Include Canada
Read more →LXRXLexicon Pharmaceuticals Completes Enrollment In Pivotal Phase 3 Clinical Trial Of Telotristat Etiprate
Lexicon Pharmaceuticals Completes Enrollment In Pivotal Phase 3 Clinical Trial Of Telotristat Etiprate
Read more →LXRXLexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2014 Fourth Quarter And Full Year Financial Results
Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2014 Fourth Quarter And Full Year Financial Results
Read more →LXRXLexicon To Report Fourth Quarter And Year End 2014 Financial Results On March 4, 2015
Lexicon To Report Fourth Quarter And Year End 2014 Financial Results On March 4, 2015
Read more →LXRXLexicon To Present At The Cowen 35th Annual Health Care Conference
Lexicon To Present At The Cowen 35th Annual Health Care Conference
Read more →LXRXLexicon Announces Management Change
Lexicon Announces Management Change
Read more →LXRXLexicon To Present At The BIO CEO & Investor Conference
Lexicon To Present At The BIO CEO & Investor Conference
Read more →LXRXLexicon To Present At The 33rd Annual J.P. Morgan Healthcare Conference
Lexicon To Present At The 33rd Annual J.P. Morgan Healthcare Conference
Read more →LXRXLexicon To Present At The Oppenheimer 25th Annual Healthcare Conference
Lexicon To Present At The Oppenheimer 25th Annual Healthcare Conference
Read more →LXRXLexicon Announces Completion Of $280 Million In Financing Transactions
Lexicon Announces Completion Of $280 Million In Financing Transactions
Read more →LXRXLexicon Announces Pricing Of Convertible Senior Notes Offering
Lexicon Announces Pricing Of Convertible Senior Notes Offering
Read more →LXRXLexicon Announces Pricing Of Common Stock Offering
Lexicon Announces Pricing Of Common Stock Offering
Read more →LXRXLEXICON ANNOUNCES PRICING OF COMMON STOCK OFFERING The Woodlands, Texas
LEXICON ANNOUNCES PRICING OF COMMON STOCK OFFERING The Woodlands, Texas, November 20, 2014 Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the pricing of its previously announced underwritten public offering of $50,000,000 of shares of its common stock pursuant to
Read more →LXRXLexicon Announces Proposed Common Stock Offering
Lexicon Announces Proposed Common Stock Offering
Read more →LXRXLexicon Announces Proposed Convertible Senior Notes Offering
Lexicon Announces Proposed Convertible Senior Notes Offering
Read more →LXRXLexicon Strengthens Clincial Operations And Commercial Readiness
Lexicon Strengthens Clincial Operations And Commercial Readiness
Read more →LXRXLEXICON PHARMACEUTICALS PROVIDES CLINICAL PIPELINE UPDATE AND REPORTS 2014 THIRD QUARTER FINANCIAL RESULTS Conference Call and Webcast at 5:00 p.m. Eastern Time The Woodlands, Texas
LEXICON PHARMACEUTICALS PROVIDES CLINICAL PIPELINE UPDATE AND REPORTS 2014 THIRD QUARTER FINANCIAL RESULTS Conference Call and Webcast at 5:00 p.m. Eastern Time The Woodlands, Texas, November 4, 2014 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company f
Read more →LXRXLexicon To Report Third Quarter 2014 Financial Results On November 4, 2014
Lexicon To Report Third Quarter 2014 Financial Results On November 4, 2014
Read more →LXRXLexicon and Ipsen enter into ex-North America/Japan licensing and commercialization agreement for telotristat etiprate
Lexicon and Ipsen enter into ex-North America/Japan licensing and commercialization agreement for telotristat etiprate
Read more →LXRXLexicon Announces A Publication In The American Diabetes Association's Journal, Diabetes Care
Lexicon Announces A Publication In The American Diabetes Association's Journal, Diabetes Care
Read more →LXRXLexicon To Present At The Morgan Stanley 2014 Global Healthcare Conference
Lexicon To Present At The Morgan Stanley 2014 Global Healthcare Conference
Read more →LXRXLexicon To Present At The 2014 Wedbush Life Sciences Management Access Conference
Lexicon To Present At The 2014 Wedbush Life Sciences Management Access Conference
Read more →LXRXLEXICON PHARMACEUTICALS PROVIDES CLINICAL PIPELINE UPDATE AND REPORTS 2014 SECOND QUARTER FINANCIAL RESULTS Conference Call and Webcast at 11:00 a.m. Eastern Time The Woodlands, Texas
LEXICON PHARMACEUTICALS PROVIDES CLINICAL PIPELINE UPDATE AND REPORTS 2014 SECOND QUARTER FINANCIAL RESULTS Conference Call and Webcast at 11:00 a.m. Eastern Time The Woodlands, Texas, August 7, 2014 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company fo
Read more →LXRXLexicon To Report Second Quarter 2014 Financial Results On August 7, 2014
Lexicon To Report Second Quarter 2014 Financial Results On August 7, 2014
Read more →LXRXLexicon And JDRF Collaborate For Phase 2 Clinical Trial Of LX4211 In Type 1 Diabetes
Lexicon And JDRF Collaborate For Phase 2 Clinical Trial Of LX4211 In Type 1 Diabetes
Read more →LXRXLexicon Announces Appointment of Lonnel Coats as President and Chief Executive Officer
Lexicon Announces Appointment of Lonnel Coats as President and Chief Executive Officer
Read more →LXRXLexicon Presents LX4211 Data at American Diabetes Association Meeting
Lexicon Presents LX4211 Data at American Diabetes Association Meeting
Read more →LXRXLexicon To Present At The Jefferies 2014 Global Healthcare Conference
Lexicon To Present At The Jefferies 2014 Global Healthcare Conference
Read more →LXRXLexicon To Present At The 2014 Bank of America Merrill Lynch Healthcare Conference
Lexicon To Present At The 2014 Bank of America Merrill Lynch Healthcare Conference
Read more →LXRXLEXICON PHARMACEUTICALS PROVIDES CLINICAL PIPELINE UPDATE AND REPORTS 2014 FIRST QUARTER FINANCIAL RESULTS Conference Call and Webcast at 11:00 a.m. Eastern Time The Woodlands, Texas
LEXICON PHARMACEUTICALS PROVIDES CLINICAL PIPELINE UPDATE AND REPORTS 2014 FIRST QUARTER FINANCIAL RESULTS Conference Call and Webcast at 11:00 a.m. Eastern Time The Woodlands, Texas, May 8, 2014 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focuse
Read more →LXRXLX4211 Achieves Positive Results In Type 1 Diabetes Clinical Trial
LX4211 Achieves Positive Results In Type 1 Diabetes Clinical Trial
Read more →LXRXLexicon To Present At The 2014 Needham Healthcare Conference
Lexicon To Present At The 2014 Needham Healthcare Conference
Read more →LXRXLexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2013 Fourth Quarter And Full Year Financial Results
Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2013 Fourth Quarter And Full Year Financial Results
Read more →LXRXLexicon to Report Fourth Quarter and Year End 2013 Financial Results on February 28, 2014
Lexicon to Report Fourth Quarter and Year End 2013 Financial Results on February 28, 2014
Read more →LXRXLexicon To Present At The BIO CEO And Investor Conference
Lexicon To Present At The BIO CEO And Investor Conference
Read more →LXRXLexicon Announces Focus On Late-Stage Development Programs And Preparation For Commercialization
Lexicon Announces Focus On Late-Stage Development Programs And Preparation For Commercialization
Read more →LXRXLexicon To Present At The J.P. Morgan Healthcare Conference
Lexicon To Present At The J.P. Morgan Healthcare Conference
Read more →LXRXLexicon Completes Phase 2 Study Of LX1033 In IBS-d
Lexicon Completes Phase 2 Study Of LX1033 In IBS-d
Read more →LXRXLexicon Pharmaceuticals To Host 2013 Research And Development Day
Lexicon Pharmaceuticals To Host 2013 Research And Development Day
Read more →LXRXLexicon To Present At The Jefferies Global Healthcare Conference
Lexicon To Present At The Jefferies Global Healthcare Conference
Read more →LXRXLexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2013 Third Quarter Financial Results
Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2013 Third Quarter Financial Results
Read more →LXRXLexicon To Present At The Credit Suisse Healthcare Conference
Lexicon To Present At The Credit Suisse Healthcare Conference
Read more →LXRXLexicon To Report Third Quarter Financial Results On November 12, 2013
Lexicon To Report Third Quarter Financial Results On November 12, 2013
Read more →LXRXLexicon Completes Pilot Study Of Telotristat Etiprate In Ulcerative Colitis
Lexicon Completes Pilot Study Of Telotristat Etiprate In Ulcerative Colitis
Read more →LXRXLX4211 Achieves Positive Results in Type 2 Diabetes Patients with Renal Impairment
LX4211 Achieves Positive Results in Type 2 Diabetes Patients with Renal Impairment
Read more →LXRXLexicon To Present At The Stifel Nicolaus Healthcare Conference
Lexicon To Present At The Stifel Nicolaus Healthcare Conference
Read more →LXRXLexicon To Present At The Morgan Stanley Global Healthcare Conference
Lexicon To Present At The Morgan Stanley Global Healthcare Conference
Read more →LXRXLexicon To Present At The Wedbush PacGrow Life Sciences Management Access Conference
Lexicon To Present At The Wedbush PacGrow Life Sciences Management Access Conference
Read more →LXRXLexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2013 Second Quarter Financial Results
Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2013 Second Quarter Financial Results
Read more →LXRXLexicon to Report Second Quarter Financial Results on July 30, 2013
Lexicon to Report Second Quarter Financial Results on July 30, 2013
Read more →LXRXLexicon Presents Preclinical Data On LX2761, a New Clinical Candidate for Diabetes Designed to Reduce Glucose Absorption From Gastrointestinal Tract
Lexicon Presents Preclinical Data On LX2761, a New Clinical Candidate for Diabetes Designed to Reduce Glucose Absorption From Gastrointestinal Tract
Read more →LXRXLexicon Presents Data at the American Diabetes Association Meeting On Blood Pressure Reduction and Weight Loss In Clinical Trial of LX4211
Lexicon Presents Data at the American Diabetes Association Meeting On Blood Pressure Reduction and Weight Loss In Clinical Trial of LX4211
Read more →LXRXJohn Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations
John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations
Read more →LXRXLexicon To Present At The Goldman Sachs Global Healthcare Conference
Lexicon To Present At The Goldman Sachs Global Healthcare Conference
Read more →LXRXLexicon To Present At The Deutsche Bank dbAccess Healthcare Conference
Lexicon To Present At The Deutsche Bank dbAccess Healthcare Conference
Read more →LXRXLexicon To Present At The Bank of America Merrill Lynch Healthcare Conference
Lexicon To Present At The Bank of America Merrill Lynch Healthcare Conference
Read more →LXRXLEXICON PHARMACEUTICALS PROVIDES CLINICAL PIPELINE UPDATE AND REPORTS 2013 FIRST QUARTER FINANCIAL RESULTS Conference Call and Webcast at 11:00 a.m. Eastern Time The Woodlands, Texas
LEXICON PHARMACEUTICALS PROVIDES CLINICAL PIPELINE UPDATE AND REPORTS 2013 FIRST QUARTER FINANCIAL RESULTS Conference Call and Webcast at 11:00 a.m. Eastern Time The Woodlands, Texas, May 10, 2013 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focus
Read more →LXRXLexicon Advances LX4211 In Type 1 Diabetes Phase 2 Trial
Lexicon Advances LX4211 In Type 1 Diabetes Phase 2 Trial
Read more →LXRXLexicon to Report First Quarter Financial Results on May 10, 2013
Lexicon to Report First Quarter Financial Results on May 10, 2013
Read more →LXRXLexicon To Present At The Needham Healthcare Conference
Lexicon To Present At The Needham Healthcare Conference
Read more →LXRXLexicon To Present At The RBC Capital Markets Healthcare Conference
Lexicon To Present At The RBC Capital Markets Healthcare Conference
Read more →LXRXLEXICON PHARMACEUTICALS PROVIDES CLINICAL PIPELINE UPDATE AND REPORTS 2012 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS Conference Call and Webcast at 11:00 a.m. Eastern Time The Woodlands, Texas
LEXICON PHARMACEUTICALS PROVIDES CLINICAL PIPELINE UPDATE AND REPORTS 2012 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS Conference Call and Webcast at 11:00 a.m. Eastern Time The Woodlands, Texas, February 21, 2013 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmac
Read more →LXRXLexicon to Report Fourth Quarter and Year End 2012 Financial Results on February 21, 2013
Lexicon to Report Fourth Quarter and Year End 2012 Financial Results on February 21, 2013
Read more →LXRXLexicon's Drug Candidate For Irritable Bowel Syndrome Receives Fast Track Status From The FDA
Lexicon's Drug Candidate For Irritable Bowel Syndrome Receives Fast Track Status From The FDA
Read more →LXRXLexicon Pharmaceuticals To Present At The Piper Jaffray Annual Healthcare Conference
Lexicon Pharmaceuticals To Present At The Piper Jaffray Annual Healthcare Conference
Read more →LXRXLexicon Pharmaceuticals to Present at the Jefferies 2012 Global Healthcare Conference
Lexicon Pharmaceuticals to Present at the Jefferies 2012 Global Healthcare Conference
Read more →LXRXLEXICON PHARMACEUTICALS REPORTS ON CLINICAL PROGRAM STATUS AND 2012 THIRD QUARTER RESULTS Conference Call at 11:00 a.m. Eastern Time The Woodlands, Texas
LEXICON PHARMACEUTICALS REPORTS ON CLINICAL PROGRAM STATUS AND 2012 THIRD QUARTER RESULTS Conference Call at 11:00 a.m. Eastern Time The Woodlands, Texas, November 6, 2012 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakt
Read more →LXRXLX4211 Phase 2b Results Presented At American Heart Association Annual Conference
LX4211 Phase 2b Results Presented At American Heart Association Annual Conference
Read more →LXRXLexicon to Provide Third Quarter 2012 Financial Results
Lexicon to Provide Third Quarter 2012 Financial Results
Read more →LXRXLexicon Initiates Phase 3 Clinical Trial Of Telotristat Etiprate In Patients With Carcinoid Syndrome
Lexicon Initiates Phase 3 Clinical Trial Of Telotristat Etiprate In Patients With Carcinoid Syndrome
Read more →LXRXSecond Phase 2 Trial Of Telotristat Etiprate Shows Positive Results In Carcinoid Syndrome
Second Phase 2 Trial Of Telotristat Etiprate Shows Positive Results In Carcinoid Syndrome
Read more →LXRXLexicon Pharmaceuticals To Present At The Morgan Stanley Global Healthcare Conference
Lexicon Pharmaceuticals To Present At The Morgan Stanley Global Healthcare Conference
Read more →LXRXLexicon Pharmaceuticals To Present At The Stifel Nicolaus 2012 Healthcare Conference
Lexicon Pharmaceuticals To Present At The Stifel Nicolaus 2012 Healthcare Conference
Read more →LXRXLexicon Pharmaceuticals To Present At The Wedbush PacGrow 2012 Management Access Conference
Lexicon Pharmaceuticals To Present At The Wedbush PacGrow 2012 Management Access Conference
Read more →LXRXLexicon Pharmaceuticals Reports on Clinical Program Status and 2012 Second Quarter Results Conference Call at 11:00 a.m. Eastern Time The Woodlands, Texas
Lexicon Pharmaceuticals Reports on Clinical Program Status and 2012 Second Quarter Results Conference Call at 11:00 a.m. Eastern Time The Woodlands, Texas, July 31, 2012 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthro
Read more →LXRXLexicon to Provide Second Quarter 2012 Financial Results
Lexicon to Provide Second Quarter 2012 Financial Results
Read more →LXRXLexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
Read more →LXRXLexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
Read more →LXRXLexicon Pharmaceuticals to present at the Jefferies 2012 Global Healthcare Conference
Lexicon Pharmaceuticals to present at the Jefferies 2012 Global Healthcare Conference
Read more →LXRXLexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
Read more →LXRXLEXICON PHARMACEUTICALS REPORTS ON CLINICAL PROGRAM STATUS AND 2012 FIRST QUARTER RESULTS Conference Call at 11:00 a.m. Eastern Time The Woodlands, Texas
LEXICON PHARMACEUTICALS REPORTS ON CLINICAL PROGRAM STATUS AND 2012 FIRST QUARTER RESULTS Conference Call at 11:00 a.m. Eastern Time The Woodlands, Texas, May 3, 2012 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthroug
Read more →LXRXLexicon to Provide First Quarter 2012 Financial Results
Lexicon to Provide First Quarter 2012 Financial Results
Read more →LXRXLexicon Pharmaceuticals to Present at the 11th Annual Needham Healthcare Conference
Lexicon Pharmaceuticals to Present at the 11th Annual Needham Healthcare Conference
Read more →LXRXFDA Grants Lexicon Orphan Drug Designation for Telotristat Etiprate for the Treatment of Carcinoid Syndrome
FDA Grants Lexicon Orphan Drug Designation for Telotristat Etiprate for the Treatment of Carcinoid Syndrome
Read more →LXRXLexicon Pharmaceuticals to Present at the Cowen and Company 32nd Annual Health Care Conference
Lexicon Pharmaceuticals to Present at the Cowen and Company 32nd Annual Health Care Conference
Read more →LXRXLexicon Pharmaceuticals to Present at the RBC Healthcare Conference
Lexicon Pharmaceuticals to Present at the RBC Healthcare Conference
Read more →LXRXLEXICON PHARMACEUTICALS PROVIDES CLINICAL PIPELINE UPDATE AND REPORTS 2011 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS Conference Call and Webcast at 11:00 a.m. Eastern Time The Woodlands, Texas
LEXICON PHARMACEUTICALS PROVIDES CLINICAL PIPELINE UPDATE AND REPORTS 2011 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS Conference Call and Webcast at 11:00 a.m. Eastern Time The Woodlands, Texas, February 22, 2012 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmac
Read more →LXRXLexicon to Report Fourth Quarter and Year End 2011 Financial Results on February 22, 2012
Lexicon to Report Fourth Quarter and Year End 2011 Financial Results on February 22, 2012
Read more →LXRXLX4211 Enhances Effects of DPP-4 Inhibition in Patients with Type 2 Diabetes
LX4211 Enhances Effects of DPP-4 Inhibition in Patients with Type 2 Diabetes
Read more →LXRXLexicon Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
Lexicon Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
Read more →LXRXLexicon Announces Completion of Rights Offering to Stockholders
Lexicon Announces Completion of Rights Offering to Stockholders
Read more →LXRXINSTRUCTIONS FOR USE OF LEXICON PHARMACEUTICALS, INC. SUBSCRIPTION RIGHTS CERTIFICATE AND ELECTION FORM CONSULT THE SUBSCRIPTION AGENT, OR YOUR BANK OR BROKER AS TO ANY QUESTIONS The following instructions relate to a su
INSTRUCTIONS FOR USE OF LEXICON PHARMACEUTICALS, INC. SUBSCRIPTION RIGHTS CERTIFICATE AND ELECTION FORM CONSULT THE SUBSCRIPTION AGENT, OR YOUR BANK OR BROKER AS TO ANY QUESTIONS The following instructions relate to a subscription rights offering (the "Rights Offering") by Le
Read more →LXRXLexicon Announces Plans for Rights Offering to Stockholders
Lexicon Announces Plans for Rights Offering to Stockholders
Read more →LXRXLexicon to Present LX4211 Clinical and Preclinical Data at Diabetes Conference
Lexicon to Present LX4211 Clinical and Preclinical Data at Diabetes Conference
Read more →LXRXLEXICON PHARMACEUTICALS REPORTS ON CLINICAL PROGRAM STATUS AND 2011 THIRD QUARTER RESULTS Conference Call and Webcast at 11:00 a.m. Eastern Time The Woodlands, Texas
LEXICON PHARMACEUTICALS REPORTS ON CLINICAL PROGRAM STATUS AND 2011 THIRD QUARTER RESULTS Conference Call and Webcast at 11:00 a.m. Eastern Time The Woodlands, Texas, November 1, 2011 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discov
Read more →LXRXLexicon to Provide Clinical Pipeline Update and Report Third Quarter 2011 Financial Results
Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2011 Financial Results
Read more →LXRXData From Phase 2 Clinical Studies of Telotristat Etiprate in Patients With Carcinoid Syndrome to be Presented at NANTS Meeting
Data From Phase 2 Clinical Studies of Telotristat Etiprate in Patients With Carcinoid Syndrome to be Presented at NANTS Meeting
Read more →LXRXLX4211 for Diabetes Shown to Reduce Fasting and Post-Prandial Blood Sugar in Healthy Subjects
LX4211 for Diabetes Shown to Reduce Fasting and Post-Prandial Blood Sugar in Healthy Subjects
Read more →LXRXLexicon Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference
Lexicon Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference
Read more →LXRXLexicon Announces Publication of LX1031 Phase 2 Trial Results in Irritable Bowel Syndrome
Lexicon Announces Publication of LX1031 Phase 2 Trial Results in Irritable Bowel Syndrome
Read more →LXRXLEXICON PHARMACEUTICALS REPORTS ON CLINICAL PROGRAM STATUS AND 2011 SECOND QUARTER RESULTS Conference Call on
LEXICON PHARMACEUTICALS REPORTS ON CLINICAL PROGRAM STATUS AND 2011 SECOND QUARTER RESULTS Conference Call on August 9, 2011 at 1:00 p.m. Eastern Time The Woodlands, Texas, August 8, 2011 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on di
Read more →LXRXPhase 2 Trial of Lexicon's LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome
Phase 2 Trial of Lexicon's LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome
Read more →LXRXLexicon Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
Lexicon Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
Read more →LXRXLexicon Pharmaceuticals Announces Webcast of 2011 Annual R&D Day
Lexicon Pharmaceuticals Announces Webcast of 2011 Annual R&D Day
Read more →LXRXLEXICON PHARMACEUTICALS REPORTS ON CLINCIAL PROGRAM STATUS AND 2011 FIRST QUARTER RESULTS Conference Call at 11:00 a.m. Eastern Time The Woodlands, Texas
LEXICON PHARMACEUTICALS REPORTS ON CLINCIAL PROGRAM STATUS AND 2011 FIRST QUARTER RESULTS Conference Call at 11:00 a.m. Eastern Time The Woodlands, Texas, May 3, 2011 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and develop
Read more →LXRXLexicon to Provide First Quarter 2011 Financial Results
Lexicon to Provide First Quarter 2011 Financial Results
Read more →LXRXLexicon Pharmaceuticals to Present at the 10th Annual Needham Healthcare Conference
Lexicon Pharmaceuticals to Present at the 10th Annual Needham Healthcare Conference
Read more →LXRXLexicon Pharmaceuticals Appoints Dr. Pablo Lapuerta Chief Medical Officer
Lexicon Pharmaceuticals Appoints Dr. Pablo Lapuerta Chief Medical Officer
Read more →LXRXLexicon Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
Lexicon Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
Read more →LXRXLexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Fourth Quarter and Full Year Financial Results
Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Fourth Quarter and Full Year Financial Results
Read more →LXRXLexicon to Report Fourth Quarter and Year End 2010 Financial Results on February 24, 2011
Lexicon to Report Fourth Quarter and Year End 2010 Financial Results on February 24, 2011
Read more →LXRXLexicon Pharmaceuticals to Present at the 13th Annual BIO CEO & Investor Conference
Lexicon Pharmaceuticals to Present at the 13th Annual BIO CEO & Investor Conference
Read more →LXRXLexicon Pharmaceuticals Inc. is Today's Focus Stock on MicroStockProfit.com
DALLAS, Jan. 7, 2011 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Lexicon Pharmaceuticals Inc. (Nasdaq:LXRX). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated inv
Read more →LXRXLexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients
Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients
Read more →LXRXLexicon Pharmaceuticals to Present at the 29th Annual JPMorgan Healthcare Conference
Lexicon Pharmaceuticals to Present at the 29th Annual JPMorgan Healthcare Conference
Read more →LXRXLexicon Announces Top-Line Phase 2a Data for LX2931 in Patients with Rheumatoid Arthritis
Lexicon Announces Top-Line Phase 2a Data for LX2931 in Patients with Rheumatoid Arthritis
Read more →LXRXLexicon Pharmaceuticals to Present at 5th Annual Canaccord Genuity Cardiovascular, Diabetes & Obesity Conference
Lexicon Pharmaceuticals to Present at 5th Annual Canaccord Genuity Cardiovascular, Diabetes & Obesity Conference
Read more →LXRXLEXICON PHARMACEUTICALS PROVIDES CLINICAL PIPELINE UPDATE AND REPORTS 2010 THIRD QUARTER FINANCIAL RESULTS Conference Call and Webcast at 11:00 a.m. Eastern Time The Woodlands, Texas
LEXICON PHARMACEUTICALS PROVIDES CLINICAL PIPELINE UPDATE AND REPORTS 2010 THIRD QUARTER FINANCIAL RESULTS Conference Call and Webcast at 11:00 a.m. Eastern Time The Woodlands, Texas, November 5, 2010 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company f
Read more →LXRXLexicon to Provide Clinical Pipeline Update and Report Third Quarter 2010 Financial Results
Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2010 Financial Results
Read more →LXRXLexicon Pharmaceuticals to Present at BioCentury Newsmakers in the Biotech Industry Conference Oct. 22nd
Lexicon Pharmaceuticals to Present at BioCentury Newsmakers in the Biotech Industry Conference Oct. 22nd
Read more →LXRXLexicon to Present at Stifel Nicolaus Healthcare Conference
Lexicon to Present at Stifel Nicolaus Healthcare Conference
Read more →LXRXLexicon to Present at Morgan Stanley Global Healthcare Conference
Lexicon to Present at Morgan Stanley Global Healthcare Conference
Read more →LXRXLEXICON PHARMACEUTICALS PROVIDES CLINICAL PIPELINE UPDATE AND REPORTS 2010 SECOND QUARTER FINANCIAL RESULTS Conference Call and Webcast at 11:00 a.m. Eastern Time The Woodlands, Texas
LEXICON PHARMACEUTICALS PROVIDES CLINICAL PIPELINE UPDATE AND REPORTS 2010 SECOND QUARTER FINANCIAL RESULTS Conference Call and Webcast at 11:00 a.m. Eastern Time The Woodlands, Texas, August 9, 2010 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company fo
Read more →LXRXLexicon to Provide Clinical Pipeline Update and Report Second Quarter 2010 Financial Results
Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2010 Financial Results
Read more →LXRXLexicon Pharmaceuticals Announces Reacquisition of All Rights to Symphony Icon Programs
Lexicon Pharmaceuticals Announces Reacquisition of All Rights to Symphony Icon Programs
Read more →LXRXLexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
Read more →LXRXLexicon to Present Clinical Data for Diabetes Drug Candidate, LX4211, at Two Major Healthcare Conferences
Lexicon to Present Clinical Data for Diabetes Drug Candidate, LX4211, at Two Major Healthcare Conferences
Read more →LXRXLexicon to Present at Two Major Healthcare Investor Conferences
Lexicon to Present at Two Major Healthcare Investor Conferences
Read more →LXRXLEXICON PHARMACEUTICALS PROVIDES CLINICAL PIPELINE UPDATE AND REPORTS 2010 FIRST QUARTER RESULTS CONFERENCE CALL AND WEBCAST AT 11:00 A.M. EASTERN TIME The Woodlands, Texas
LEXICON PHARMACEUTICALS PROVIDES CLINICAL PIPELINE UPDATE AND REPORTS 2010 FIRST QUARTER RESULTS CONFERENCE CALL AND WEBCAST AT 11:00 A.M. EASTERN TIME The Woodlands, Texas, May 10, 2010 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on disc
Read more →LXRXLexicon Presents Positive Outcome in IBS Patients Treated With LX1031 and Data Supporting Mechanism of Action
Lexicon Presents Positive Outcome in IBS Patients Treated With LX1031 and Data Supporting Mechanism of Action
Read more →LXRXLexicon to Provide Clinical Pipeline Update and Report First Quarter 2010 Financial Results
Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2010 Financial Results
Read more →LXRXLexicon to Present at BIO International Convention
Lexicon to Present at BIO International Convention
Read more →LXRXLexicon to Present Phase 2 Clinical Data for IBS Drug Candidate at Digestive Disease Week
Lexicon to Present Phase 2 Clinical Data for IBS Drug Candidate at Digestive Disease Week
Read more →LXRXLexicon Pharmaceuticals Announces Webcast of 2010 Annual R&D Day
Lexicon Pharmaceuticals Announces Webcast of 2010 Annual R&D Day
Read more →LXRXLexicon Pharmaceuticals 2009 Annual Report to Stockholders Available Online
Lexicon Pharmaceuticals 2009 Annual Report to Stockholders Available Online
Read more →LXRXLexicon Announces Completion of Common Stock Offering
Lexicon Announces Completion of Common Stock Offering
Read more →LXRXLEXICON ANNOUNCES PRICING OF COMMON STOCK IN PUBLIC OFFERING The Woodlands, Texas
LEXICON ANNOUNCES PRICING OF COMMON STOCK The Woodlands, Texas, March 16, 2010 Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the pricing of a public offering and concurrent private placement of its common stock in which the aggregate net proceeds to Lexicon will
Read more →LXRXLexicon Announces Proposed $95 Million Common Stock Offering
Lexicon Announces Proposed $95 Million Common Stock Offering
Read more →LXRXLexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Fourth Quarter and Full Year Financial Results
Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Fourth Quarter and Full Year Financial Results
Read more →LXRXLexicon to Report Fourth Quarter and Year End 2009 Financial Results on February 23, 2010
Lexicon to Report Fourth Quarter and Year End 2009 Financial Results on February 23, 2010
Read more →LXRXLexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Read more →LXRXLexicon to Host Conference Call and Webcast to Review Top-Line Phase 2 Results From Diabetes Trial
Lexicon to Host Conference Call and Webcast to Review Top-Line Phase 2 Results From Diabetes Trial
Read more →LXRXPhase 2 Trial of LX4211 Demonstrates Significant and Rapid Improvements in Multiple Parameters in Type 2 Diabetic Patients
Phase 2 Trial of LX4211 Demonstrates Significant and Rapid Improvements in Multiple Parameters in Type 2 Diabetic Patients
Read more →LXRXLexicon Pharmaceuticals Reports 2008 Fourth Quarter and Full Year Financial Results
THE WOODLANDS, Texas, Feb. 25, 2009 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial res
Read more →LXRXLexicon to Report Fourth Quarter and Year End 2008 Financial Results On February 25, 2009
THE WOODLANDS, Texas, Feb. 18, 2009 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX) will release its fourth quarter and year end 2008 financial results on Wednesday, February 25, 2009 before the financial markets open. Lexicon management will hold a conference cal
Read more →LXRXLexicon Consolidates Operations to Focus Resources On Most Advanced Drug Discovery and Development Programs
THE WOODLANDS, Texas, Jan. 22, 2009 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today a restructuring of its operations to conserve capital
Read more →LXRXLexicon Initiates Phase 2 Clinical Trial of LX1031 in Patients With Irritable Bowel Syndrome
THE WOODLANDS, Texas, Jan. 12, 2009 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it has initiated a Phase 2 clinical trial of LX10
Read more →LXRXLexicon Pharmaceuticals to Present At the 27th Annual JPMorgan Healthcare Conference
THE WOODLANDS, Texas, Jan. 8, 2009 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX) announced today that Arthur T. Sands, M.D., Ph.D., Lexicon's president and chief executive officer, will present at the JPMorgan Healthcare Conference at The Westin St. Francis Hote
Read more →LXRXLexicon's Drug Candidate LX6171 for Cognitive Disorders Completes Phase 2A Clinical Trial
* No Significant Cognitive Effects Observed in Subjects with Age-Associated Memory Impairment * Future LX6171 Clinical Development Plans to be Re-evaluated * Phase 2 Development Resources to be Focused on LX1031 for Irritable Bowel Syndrome and LX1032 for Carcinoid Syndrome
Read more →LXRXLexicon Files Investigational New Drug Application for LX4211 as a Potential Treatment for Diabetes
* New Oral Small Molecule Drug Candidate for Type 2 Diabetes * SGLT2 Inhibition Shown to Reduce Blood Glucose Levels and Body * Phase 1 Clinical Trials to Begin Following FDA Review THE WOODLANDS, Texas, Dec. 1, 2008 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LX
Read more →LXRXLexicon Pharmaceuticals Announces Webcast of Annual R&D Day
THE WOODLANDS, Texas, Nov. 25, 2008 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX) announced today that it will hold its Annual R&D Day on Tuesday, December 2, 2008 from 8:00 a.m. to 11:00 a.m. Eastern Time in New York, New York. Members of Lexicon's senior manag
Read more →LXRXLexicon Pharmaceuticals to Present At Two Upcoming Healthcare Conferences
THE WOODLANDS, Texas, Nov. 24, 2008 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX) announced today that members of Lexicon senior management will present at the following healthcare conferences: -- Piper Jaffray 20th Annual Health Care Conference at The New Yor
Read more →LXRXLexicon's Drug Candidate LX1032 for Carcinoid Syndrome Successfully Completes Phase 1 Clinical Trials
* Drug Candidate Will Advance to Phase 2 Clinical Trial in Carcinoid * Potent Reduction in Serotonin Achieved * Drug Candidate Being Developed Under Fast Track Status From FDA THE WOODLANDS, Texas, Nov. 13, 2008 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX),
Read more →LXRXLexicon Pharmaceuticals Reports 2008 Third Quarter Financial Results
THE WOODLANDS, Texas, Oct. 30, 2008 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial res
Read more →LXRXLexicon Presents Phase 1 Clinical Trial Results for LX2931 At American College of Rheumatology Annual Meeting
* New Small Molecule Drug Candidate for Rheumatoid Arthritis and Other Autoimmune Diseases * Novel Mechanism of Action of Immune Modulation Shows Activity in * LX2931 to Progress to Next Stage of Clinical Development in THE WOODLANDS, Texas, Oct. 25, 2008 (GLOBE NEWSWIRE) --
Read more →LXRXLexicon to Report Third Quarter 2008 Financial Results On October 30, 2008
THE WOODLANDS, Texas, Oct. 16, 2008 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX) will release its third quarter 2008 financial results on Thursday, October 30, 2008 before the financial markets open. Lexicon management will hold a conference call to discuss its
Read more →LXRXLexicon to Present Clinical Data for LX2931, an Investigational New Drug for Rheumatoid Arthritis
THE WOODLANDS, Texas, Oct. 14, 2008 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that the company will be presenting initial Phase 1 cl
Read more →LXRXLexicon Pharmaceuticals Identifies New Drug Candidate for Glaucoma
* Novel Target for Regulating Intraocular Pressure in the Eye * Currently No Marketed Drugs Targeting LX7101 Mechanism of Action * Glaucoma Affects 4 Million Americans, 65 Million Worldwide * Lexicon Now Has Six Drug Candidates in Development THE WOODLANDS, Texas, Aug. 12, 20
Read more →LXRXLexicon Pharmaceuticals Reports 2008 Second Quarter Financial Results
Five Clinical Programs Anticipated by Year-End Conference Call and Webcast At 11:00 a.m. Eastern Time THE WOODLANDS, Texas, July 29, 2008 (PRIME NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), a biopharmaceutical company focused on discovering and developing breakthro
Read more →LXRXLexicon Pharmaceuticals' Drug Candidate for Irritable Bowel Syndrome Completes Phase 1 Clinical Trial Showing Positive Results
THE WOODLANDS, Texas, July 29, 2008 (PRIME NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it has successfully completed a Phase 1 multiple-
Read more →LXRXLexicon to Report Second Quarter 2008 Financial Results On July 29, 2008
THE WOODLANDS, Texas, July 17, 2008 (PRIME NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX) will release its second quarter 2008 financial results on Tuesday, July 29, 2008 before the financial markets open. Lexicon management will hold a conference call to discuss its cl
Read more →LXRXLexicon's Drug Candidate for Carcinoid Syndrome Receives Fast Track Status From the FDA
THE WOODLANDS, Texas, June 3, 2008 (PRIME NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it has received Fast Track status from the U.S. Fo
Read more →LXRXLexicon Pharmaceuticals Implements Reorganization to Deploy Resources Toward Drug Development Pipeline
THE WOODLANDS, Texas, May 28, 2008 (PRIME NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX) announced today that it is implementing a reorganization designed to reduce costs and increase efficiencies in its research and discovery operations. This action will further focus
Read more →LXRXLexicon Pharmaceuticals to Present At the Bank of America Health Care Conference
THE WOODLANDS, Texas, May 8, 2008 (PRIME NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX) announced today that a member of Lexicon senior management will present at the Bank of America Health Care Conference at the Four Seasons Hotel in Las Vegas, Nevada on Wednesday, May
Read more →LXRXLexicon Pharmaceuticals Reports 2008 First Quarter Financial Results
THE WOODLANDS, Texas, April 29, 2008 (PRIME NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial re
Read more →LXRXLexicon Pharmaceuticals to Present At the Morgan Stanley Global Healthcare Unplugged Conference
THE WOODLANDS, Texas, April 24, 2008 (PRIME NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX) announced today that members of Lexicon senior management will present at the Morgan Stanley Global Healthcare Unplugged Conference at The Ritz-Carlton in Key Biscayne, Florida on
Read more →LXRXLexicon to Report First Quarter 2008 Financial Results On April 29, 2008
THE WOODLANDS, Texas, April 21, 2008 (PRIME NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX) will release its first quarter 2008 financial results on Tuesday, April 29, 2008 after the financial markets close. Lexicon management will hold a conference call to discuss its c
Read more →LXRXLexicon's Drug Candidate for Rheumatoid Arthritis, LX2931, Shows Positive Results in Phase 1 Clinical Trial
THE WOODLANDS, Texas, April 17, 2008 (PRIME NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), a leader in genomics-based drug discovery, announced today that it has obtained positive results from its initial Phase 1 clinical trial of LX2931, an orally-delivered, small mol
Read more →LXRXLexicon Presents Clinical Data for LX6171, a Drug Candidate for Cognitive Disorders
THE WOODLANDS, Texas, April 15, 2008 (PRIME NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), a leader in genomics-based drug discovery, presented data today describing the target of LX6171 and initial Phase 1 clinical results at the American Academy of Neurology in Chica
Read more →LXRXLexicon Pharmaceuticals to Present At the Future Leaders in the Biotech Industry Conference
THE WOODLANDS, Texas, March 20, 2008 (PRIME NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX) announced today that a member of Lexicon senior management will present at the Future Leaders in the Biotech Industry Conference at the Millennium Broadway Hotel in New York, New
Read more →LXRXLexicon Pharmaceuticals 2007 Annual Report to Stockholders Available Online
THE WOODLANDS, Texas, March 14, 2008 (PRIME NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today made available its 2007 annual report to stockholders on the Le
Read more →LXRXLexicon Pharmaceuticals Reports 2007 Fourth Quarter and Full Year Financial Results
THE WOODLANDS, Texas, March 6, 2008 (PRIME NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial res
Read more →Competitive Position
How LXRX ranks across every disease it competes inCompetitive Position is a premium feature
See how LXRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial